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Abstract:  
Inducing macromolecular interactions with small molecules to activate cellular signaling is a 
challenging goal. PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that 
recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. 
Structural elucidation of the key ternary species ligase:PROTAC:target and how this impacts 
target degradation selectivity remains elusive. We solved the crystal structure of Brd4-
degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4BD2). The 
ligand folds into itself to allow formation of specific intermolecular interactions in the ternary 
complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and 
proximity assays, are consistent with pronounced cooperative formation of ternary complexes 
with Brd4BD2. Structure-based designed compound AT1 exhibits highly selective depletion of 
Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate 
preferential recruitment of a target protein into stable and cooperative complex with an E3 
ligase for selective degradation.  
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Introduction 
Regulating protein function through targeted degradation as opposed to more conventional 
target inhibition has emerged as a new modality of discovery chemistry with attractive 
potential both as tools for target validation and for the development of novel therapeutics 1-4. 
PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that bring a target 
protein into spatial proximity with an E3 ubiquitin ligase to trigger target ubiquitination and 
subsequent proteasomal degradation 5-11. Recent developments in the field have led to 
PROTACs being designed with increasingly “drug-like” molecular properties, and 
remarkable activities both in cells and in vivo 10. Furthermore, we and others have shown that 
target depletion selectivity by PROTACs can significantly exceed the binding selectivity of 
their constitutive warhead ligands 7,12. This realization provides proof-of-concept for turning 
non-selective or promiscuous ligands into more selective degraders, which can be highly 
desirable for both chemical probes and drug leads. A characteristic feature of PROTACs 
mode of action is their sub-stoichiometric catalytic action that alleviates the requirement for 
target engagement and occupancy of traditional inhibitors 9. Effective redirection of a ligase 
poly-ubiquitination activity toward a new substrate protein requires formation of a ternary 
complex ligase:PROTAC:target, an intermediate species that is crucial to the cellular activity 
of degrader molecules. However, structural elucidation of such ternary species and how it 
may influence selectivity of target degradation remain elusive since the PROTAC concept 
was first incepted and demonstrated in 2001 (ref. 5).  
In 2015 we and others reported the first examples of small-molecule PROTACs that target 
the bromo- and extra-terminal (BET) family proteins for degradation by recruiting substrate-
recognition subunits von Hippel–Lindau protein (VHL) 7 and cereblon (CRBN) 6,8 of the 
respective cullin RING ligases (CRLs), CRL2VHL and CRL4CRBN. Compound MZ1 (ref. 7) 
conjugates the pan-BET inhibitor JQ1 (ref. 13) to VH032, a potent and specific VHL ligand 
14,15, via a 3-unit PEG linker (Fig. 1a). MZ1 and its analogues, MZ2 and MZ3 
(Supplementary Results, Supplementary Fig. 1), induce more effective depletion of a 
single BET member, Brd4 (a validated drug target against cancer and other diseases 16), over 
its family paralogues Brd2 and Brd3 (ref. 7). These observations led us to hypothesize a 
structural basis for target selectivity, imparted as a result of PROTAC-induced recruitment of 
the ligase and bromodomain together in a ternary complex. To reveal the molecular details of 
complex formation, we pursued the crystal structure of MZ1 in complex with VHL and a 
BET bromodomain. Here we present for the first time a structure of a PROTAC bound to 
both E3 ligase and target protein. The structure reveals MZ1 is “sandwiched” between the 
two proteins, inducing extensive new protein-protein and protein-ligand contacts of both 
hydrophobic and electrostatic nature. Biophysical binding studies in solution allowed 
measurement of full thermodynamics parameters of complex formation, which revealed 
marked isoform-specific cooperativity of ternary complexes. Surface mutagenesis swap and 
proximity binding assays data support the induced PPI contacts drive specificity of the 
cooperative recognition, impacting on the relative population of ternary complexes. 
Furthermore, new PROTAC molecules designed guided by the crystal structure showed 
exquisite selectivity for inducing cellular depletion of Brd4 over its BET family members 
Brd2 and Brd3.  
Results  
Ternary complex crystal structure. To elucidate the structural details of PROTAC-induced 
substrate recruitment to an E3 ligase, we solved the crystal structure of MZ1 bound in a 
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ternary complex with the second bromodomain (BD) of Brd4 (Brd4BD2) and VHL to 2.7 Å 
resolution (Fig. 1a, Supplementary Table 1). The asymmetric unit of the crystal contained 
two ternary Brd4BD2:MZ1:VCB (VHL, ElonginB and ElonginC) complexes of overall 
identical quaternary architecture (Supplementary Fig. 2a) and only minor deviations at 
either end when superposed over the central VHL subunit (Supplementary Fig. 2b,c). The 
first complex (chains A, B, C and D) had lower average B factors (Supplementary Fig. 2a) 
so we refer to this in all subsequent analyses. The electron density around MZ1 was fully 
defined (see inset panel in Fig 1a and Supplementary Fig. 2d,e for each protomer in the 
asymmetric unit). MZ1 is bound within a bowl-shaped interface formed by extensive protein-
protein interactions (PPIs) between Brd4BD2 and VHL (Supplementary Fig. 3a). The bowl 
has a hydrophobic "base" which is formed by two key points of contact (Fig. 1b and 
Supplementary Fig. 3a). Firstly, Trp374 from the characteristic hydrophobic region named 
“WPF shelf” (ref. 17) of Brd4BD2 interacts with residues Arg69, Pro71 and Tyr112 of VHL 
(Fig. 1b). Pro71 provides an additional stack to the WPF, forming an extended “PWPF” shelf 
(Fig. 1b). Secondly, Ala384 and Leu385 from the second helical turn of the ZA loop of 
Brd4BD2 contact the hydrophobic side chains of Arg108, Ile109 and His110 in β4 of VHL 
(Fig. 1b). Two electrostatic "arms" complete the rim of the bowl. At one end, Asp381 and 
Glu383 in the ZA loop of Brd4BD2 form a tight zipper structure of complementary charges 
with Arg107 and Arg108 (Fig. 1c). At the opposite end Brd4BD2 residue Glu438, residing in 
the BC loop, contacts Arg69 from VHL (Fig. 1d). In the induced interface between the two 
proteins, Brd4BD2 recapitulates some of the interactions made by the HIF-1α CODD segment 
peptide with VHL 18,19, as the electrostatic zipper structure generated by Asp381 and Glu383 
contacts the same VHL residues (Arg107 and Arg108) as Asp569 and Asp571 of HIF-1α 
(Fig. 1c and Supplementary Fig. 3b,c). In contrast, VHL does not contact the surface of 
Brd4 bromodomain bound to acetyllysine histone H4 peptide 20 (Supplementary Fig. 3d,e). 
In total the PPIs induced in the complex bury a surface area of 688 Å2 (Supplementary 
Table 2). 
MZ1 is cupped within the bowl structure in such a way that its two heads recapitulate the 
binding modes of the respective ligands individually – JQ1 in the acetyllysine-binding pocket 
of Brd4BD2 13,20, and VH032 in the hydroxyproline-binding site of VHL 14 (Supplementary 
Fig. 3f,g). In addition to the expected binary protein-ligand interactions, MZ1 forms 
additional protein-ligand interactions within the ternary complex. The PEG linker makes van 
der Waals interactions with the BC loop of Brd4BD2 and a hydrogen bond between the ether 
oxygen adjacent to the amide linkage to JQ1 and the BD2-specific residue His437 (Fig. 1d). 
The same hydrogen bond between His437 and a PEG oxygen is also observed in a recent 
crystal structure of Brd4BD2 bound to MT1, a bivalent BET inhibitor comprised of two JQ1 
moieties linked by a PEG unit in a similar fashion as in MZ1 (Supplementary Fig. 4) 21. 
VHL and Brd4BD2 come together to sandwich MZ1 against their respective binding surfaces, 
burying otherwise solvent-exposed regions of the JQ1 and VH032 ligands. Specifically, 
Ala384, Leu385 and Gly386 from the ZA loop of Brd4BD2 contact the –CH2–phenyl portion 
of VH032, whilst His110 and Tyr112 of β4 of VHL contact one of the two thiophene methyl 
groups and the para-chlorophenyl ring of JQ1 (Fig. 1b). In addition, MZ1 folds onto itself in 
such a way that its PEG linker is packed between the tert-butyl group of the VH032 moiety 
and the para-chlorophenyl ring of JQ1 (Fig. 1a,d). Throughout a 100 ns molecular dynamics 
simulation, favorable intermolecular contacts were observed from JQ1 atoms to VHL, from 
VH032 atoms to Brd4BD2, and from the PEG linker atoms to both VHL and Brd4BD2, as well 
as intramolecular contacts within MZ1 involving the PEG linker and the JQ1 and VH032 
moieties (Fig. 2a and Supplementary Fig. 5). The surface area further buried by the ligand 
folding within the bowl-shaped interface was 1,933 Å2, resulting in a total extended buried 
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surface area of 2,621 Å2 for the ternary complex (see Supplementary Table 2 for a 
comparison with cereblon:phthalimides:target ternary complexes 2,3).  
Isoform-specific cooperativity of ternary complexes. The extensive new contacts observed 
in the crystal structures suggested the possibility that isoform-specific PPIs could play a role 
in the “cooperativity” of the ternary complex equilibria 22,23. To assess the thermodynamics of 
PROTAC-induced complex formation with VHL and BET BDs, we employed isothermal 
titration calorimetry (ITC) in solution (Table 1 and Supplementary Fig. 6). To disentangle 
contributions from binary and ternary complex formation equilibria we performed reverse 
titrations i.e. protein in syringe and ligand in cell. This experimental strategy avoids the 
characteristic “hook effect” observed with increasing concentrations of PROTACs, as 
formation of binary complexes competes with and eventually surpasses formation of ternary 
ones 23. First, we titrated a solution of BET BD against MZ1, ensuring no excess unbound 
PROTAC compound would be present at the end of the titration. This was followed by a 
titration of VCB into the saturated MZ1:BD complex, forming the ternary VCB:MZ1:BD 
complex (Fig. 2b, right panel). Titration of VCB into MZ1 alone (Fig. 2b, left panel) was 
then performed and used as reference, allowing potential cooperativity of ternary complex 
formation to be accurately quantified. By definition, a ternary system is considered positively 
cooperative if interactions enhance formation of the ternary complex (α = !!!(!"#$%&)!!! !"#$%#&  > 1; 
ΔpKd = pKdT (ternary) – pKd (binary) >0). Conversely, a system is termed negatively 
cooperative when formation of the ternary complex is diminished (α < 1; ΔpKd < 0), for 
example because of repulsive interactions or steric hindrance between the two components in 
the ternary complex. Non-cooperative equilibria would instead show unchanged Kd for the 
two steps (α = 1; ΔpKd = 0), suggesting no interactions (Fig. 2c). With all BET BDs used, we 
observed significant positively cooperative ternary complex formation (see Table 1, and plots 
of ΔpKd in Fig. 2d). Strikingly, the strongest cooperativity was observed for Brd4BD2 (α = 
18), followed by Brd3BD2 (α = 11; Table 1 and Fig. 2d). The large cooperativity observed led 
to steep transition of the sigmoidal binding curve (Fig. 2b, right panel), suggesting that the 
fitted Kd value could potentially be underestimating the real binding affinity of this ternary 
complex.  All BD1s also exhibited positive cooperativity, albeit to a much lesser extent (α 
between 2 and 3). Brd4BD2 and Brd3BD2 not only exhibited the greatest cooperativity amongst 
all BET BDs, they also formed the most stable ternary complexes overall (ΔG (binary + 
ternary) = –22.2 ± 0.1 and 22.0 ± 0.2 kcal/mol, respectively), ~2 kcal/mol more stable than 
e.g. Brd2BD1 (ΔG = –20.3 ± 0.2 kcal/mol).  
To understand the impact of cooperativities of different BET BDs ternary complexes on their 
relative population, we applied a mathematical model of ternary equilibrium 23. We simulated 
the fraction of ternary complex formation for VCB, MZ1 and six individual BET BDs, using 
our measured binary Kds and cooperativities α (Table 1) and protein concentrations of 40 nM 
(to be around the Kd values and to match the concentrations used later in AlphaLISA). 
Overlay of simulations showed that the relative populations of each ternary complex vary 
significantly, with Brd4BD2 being the most populated, and, as an example, ~2.5 fold greater 
than Brd2BD1 at any given concentration of PROTAC (Fig. 2e). To interrogate this relative 
trend experimentally, we employed a proximity AlphaLISA assay that can achieve high 
signal amplification in response to formation of ternary complexes over an energy transfer 
distance of up to 200 nm 24,25. At every fixed component concentration, the relative trend 
observed in AlphaLISA signal was broadly consistent with the cooperativity trends measured 
by ITC, with Brd4BD2 and Brd3BD2 giving greater signal, while Brd2BD1 giving the lowest 
response (Fig. 2f). A similar trend was observed with the analogous MZ2 (PEG4), MZ3 
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(PEG3-Phe) and MZ4 (PEG2) (Supplementary Fig. 7a–h). Taken together the data are 
consistent with target-specific cooperativities and stabilities of ternary complexes impacting 
on the relative population of this key intermediate species. 
Specificity of MZ1-induced protein-protein interactions. To evaluate to what extent the 
cooperativity of ternary complex formation is dictated by surface complementarity between 
VHL and the Brd4BD2 bromodomain, we mutated semi-conserved or non-conserved 
bromodomain residues forming key induced PPI contacts, but not directly involved in 
binding of MZ1 (Fig. 3a and Supplementary Fig. 5). Inspection of sequence alignments 
(Fig. 3a) and the crystal structure (Fig. 3b) guided us to select residues Glu383 and Ala384 in 
Brd4BD2 (the most cooperative of bromodomains), for site directed mutagenesis. These 
residues are Val106 and Lys107 in the corresponding positions in Brd2BD1, one of the least 
cooperative BET domains. In addition, the MD simulation evidenced extensive movement of 
loop 7 of VHL (ref. 26) bringing it in close contact with Lys378 of Brd4BD2 (Supplementary 
Fig. 5b–d), which corresponds to Gln101 in Brd2BD1. Based on these considerations, triple 
mutant Brd4BD2 K378Q/E383V/A384K (named QVK for simplicity) was designed. The 
mutations would make the PPI surface of Brd4BD2 closer to that of Brd2BD1, albeit with the 
caveat of introducing an extra charge overall. Conversely, a triple mutant of Brd2BD1 was 
designed in which the corresponding residues are switched to those of Brd4BD2 
(Q101K/V106E/K107A, named KEA for simplicity). In ITC, the QVK mutant exhibited 
significantly weakened cooperative complex formation relative to Brd4BD2 wild-type (WT) (α 
= 4; Table 1 and ΔpKd = 0.64 ± 0.04, see plots in Fig. 3c). Conversely, the cooperativity of 
the KEA mutant increased relative to Brd2BD1 WT (α = 8; Table 1 and Fig. 3c). Crucially, 
these mutations did not affect the Kd of each domain for MZ1 (Table 1), suggesting that the 
switch of cooperativity is independent of binary target engagement and instead is dictated by 
the induced PPIs. Consistent with the cooperativity switch measured by ITC, QVK reduced 
ternary complex formation in AlphaLISA compared to WT, whereas KEA displayed the 
opposite effect  (Fig. 3d with MZ1 and Supplementary Fig. 7i with MZ2). Taken together 
these data validate the ternary complex structure in solution and elucidate how specific PPIs 
influence cooperative recruitment of two target proteins to each other by a bifunctional 
molecule.  
Structure-designed AT1 is highly selective Brd4 degrader. In chemical probe and drug 
development knowledge of ligand-bound structures can guide the design of next-generation 
compounds. We therefore sought to create new PROTACs based on our crystal structure that 
could exhibit enhanced target depletion selectivity in cells toward Brd4. We noted that the 
side chain of the key tert-Leu group of VH032 projected an attractive vector to link directly 
to the JQ1 moiety (Fig. 4a), which we hypothesized could better discriminate against the 
relative binding orientation observed in the crystal. We therefore replaced tert-Leu with 
penicillamine and synthesized 1 (AT1, Fig. 4b) and other analogues 2–6 (AT2–AT6) bearing 
thioether linkages of varying length to JQ1 (Supplementary Fig. 1 and Methods). The 
modified VHL ligand within AT1 retained binding to VHL (Kd 330 nM, Supplementary 
Table 3, and Supplementary Fig. 8), a less than two-fold loss of potency relative to VH032 
(ref. 14) but approximately five-fold less compared to MZ1. ITC data comparing binary and 
ternary complexes revealed Brd4BD2 as the BET bromodomain forming the most cooperative 
(α = 7; ΔpKd = 0.84 ± 0.07) and most stable (ΔG = –20.2 ± 0.2 kcal/mol) of all ternary 
complexes with AT1 (Fig. 4c, Supplementary Table 3, and Supplementary Fig.  8). The 
same trend of cooperativity observed for MZ1 and the QVK and KEA mutants relative to WT 
was also observed with AT1 (Fig. 4c, Supplementary Table 3), suggesting AT1 recruits 
VHL and Brd4BD2 in the same relative orientation as does MZ1. We consistently observed by 
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AlphaLISA preferential recruitment of Brd4BD2 over the other BDs by AT1–6 (Fig. 4d and 
Supplementary Fig. 9). We next tested the activity of the new structure-designed molecules 
to induce degradation of BET proteins in cells, and observed remarkable Brd4-selective 
depletion at all concentrations tested, with depletion of Brd4 after 24 h treatment with 1–3 
µM of AT1 and negligible activity against Brd2 and Brd3 (Fig. 4e, see Supplementary Fig. 
9 for AT2–6, and full uncut gel images in Supplementary Fig. 11). Specificity for Brd4 
degradation was not due to differences in protein synthesis rates, as shown by control 
treatments with cycloheximide, which blocks protein translation (Supplementary Fig. 10). 
To assess whether ubiquitination of lysine residues could play a role in the observed 
selectivity, we combined our EloBC–VHL–MZ1–Brd4BD2 complex with existing whole CRL 
structural information into a model of the entire CRL2VHL–MZ1–bromodomain assembly 
(Supplementary Fig. 12a). Several lysine residues are surface exposed and accessible to the 
E2-Ub in this model at distances between 50–60 Å, consistent with known CRL substrates 27. 
Mapping MZ1-induced ubiquitination sites in vitro identified Lys346 on Brd4BD2 and several 
sites on the other BET-BDs (Supplementary Fig. 12b-d). Unbiased and quantitative isobaric 
tagging mass spectrometry proteomics confirmed Brd4 as the sole protein markedly depleted 
(to ~40%) upon treatment with AT1, amongst the 5,674 detected proteins that passed filtering 
criteria (Fig. 4f and Supplementary Data Set 1). Crucially, no effect on protein levels of 
Brd2 and Brd3 was observed with AT1, in contrast with MZ1 that exerted a broader and 
more profound effect across all BET proteins, albeit still preferential toward Brd4 (Fig. 4g). 
Together these data qualify AT1 as a new highly selective degrader of Brd4 in cells. 
Discussion  
We put forth a model for how cooperative recruitment of a target close to an E3 ligase in a 
ternary complex by a PROTAC molecule can impact on the effectiveness and selectivity of 
target degradation (Fig. 5). Our work shines structural insights into how bifunctional 
molecules can induce target-specific interactions in the ‘enzyme-substrate’ ternary complex 
species key for PROTAC catalytic activity. These cooperative molecular recognition features 
contribute to how tightly and stably the ‘neo-substrate’ can be bound to the ligase, impacting 
on the relative population of the complex and consequently on the catalytic efficiency of the 
process. For homologous targets as is the case with BET bromodomains, we show how these 
features add a level of target depletion selectivity independently of binary target engagement.  
We illustrate the relevance of measuring cooperativities of ternary complex formation in 
solution using ITC. One of the main advantages of the assay set-up as described here is that it 
is designed to avoid issues associated with the hook effect. While the assay may be used to 
characterize in full a handful of compounds and systems, it requires large quantities of 
material and notably lacks throughput. Alternative bioassays to quantify formation of ternary 
complexes could circumvent this limitation, and we provide evidence that proximity 
AlphaLISA assay can be used for these purposes. However, AlphaLISA data should be 
interpreted with caution, even when comparing highly conserved domains as done here, 
because in this bead-based technology the multiplicity of binding sites and relative linkage 
and orientation of components immobilized to the beads may influence the measured signal 
24,28. Moreover, it can be difficult to deconvolute individual binding parameters from dose–
response curves monitoring ternary complex formation, because these are often bell–shaped 
curves complicated by the hook effect 23. We anticipate that future assay developments in this 
direction will help prioritize complexes for structural studies and to drive drug development 
programs. The results of our study are of particular relevance because VHL-based BET 
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degraders similar to the ones described here have proven to be bioavailable and active in vivo 
29 and could potentially enter clinical trials as early as 2017 (ref. 4). 
Our study points to the importance that the bifunctional molecule “folds in itself” in such a 
way that its two heads can recruit the respective targets into productive proximity. The result 
of this process is the burial of extensive surface area, the formation of new PPIs, contributing 
to the high stability and cooperativity of ternary complexes. Our work has therefore major 
implications for future PROTAC drug design, which has so far been somewhat empirical and 
has largely adopted a combinatorial “plug-and-play” strategy 11. The proposed model 
suggests that bifunctional molecules should be rationally designed and prioritized based on 
their ability to induce favorable contacts and allow forming a stable complex between the E3 
ligase and the target. While ligand-induced proximity is expected to strengthen potential PPIs 
because of the reduced entropic cost, we show that the level of surface complementarity 
between the two proteins in their relative orientation imposed by the bifunctional molecule 
dictates cooperative complexation. While the exact relative orientation between VHL and 
Brd4 observed in the crystal may not be the only one that the system can adopt in solution 
once free from potential constraints of crystal packing, our data suggests that it captures a 
significant species underlying MZ1 function. Maximizing the diversity of E3s recruited 30, 
and linking positions and vectors from the E3 and target ligands, will thus be important to 
achieve target-specific degraders. 
In an example of first layer of this rational design, we show how new PROTACs designed 
based on our ternary structure can lead to enhanced selectivity of depletion in cells for the 
crystallized target Brd4. The efficiency and selectivity of cellular protein knockdown will 
inevitably depend on other factors, including compound permeability and stability, the 
expression level of the hijacked CRL and its relative activity and flexibility 27,31, as well as 
target abundance and re-synthesis rates. Differing ubiquitination rates could also in principle 
influence target degradation selectivity. To this end, in addition to increasing their relative 
population, cooperative and stable complexes would be expected to exhibit slower 
dissociation rates and longer half-lives, potentially aiding the efficiency of target 
ubiquitination by the hijacked ligase. Differing availability and access of surface lysine 
residues between alternate substrates could also play a role. However, based on our data, the 
presence of many surface Lys on BET-BDs, and the flexibility and large ubiquitination zone 
of CRLs 2,27, we view it unlikely that target ubiquitination plays a role in the observed 
selectivity of Brd4 degradation. Obtaining a more detailed biochemical picture of target 
ubiquitination in a cellular context will be of clear importance for future investigation. 
For targeted protein degradation, converting a pan-selective or promiscuous probe ligand into 
a more selective degrader probe provides new opportunities to improve target validation and 
could minimize off-target effects. In addition to dictate selectivity of target degradation, 
highly cooperative ternary E3:PROTAC:target systems would be anticipated to unlock the 
possibility to effectively degrade hitherto “undruggable” targets using ligands with inherently 
weak binary binding affinities. A more general implication of this study is the feasibility to 
induce de novo protein-protein interactions, or stabilize weakened ones, using bifunctional 
small molecules, a feature previously established with mono-functional ‘molecular glues’ 32 
such as the plant hormones auxin 33 and jasmonate 34, the phthalimide immunomodulatory 
drugs (IMiDs) 2,3,31,35-38, and macrocyclic natural products such as rapamycin and 
cyclosporine 39,40. We envision that extensions of PPI-stabilizing capabilities to hetero- or 
homo-bifunctional small molecules 21,41,42 beyond PROTACs as highlighted here could 
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expand the target spectrum accessible to PPI stabilizers, and provide a new paradigm of 
selective chemical intervention for structural chemical biology and drug discovery. 
 
METHODS 
Methods and any associated references are available in the online version of the paper. 
Accession codes 
Atomic coordinates and structure factors for hsBrd4BD2–MZ1–hsVHL–hsEloC–hsEloB have 
been deposited in the Protein Data Bank (PDB) under accession number 5T35.  
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Any supplementary information, chemical compound information and source data are 
available in the online version of the paper. Correspondence and requests for materials should 
be addressed to A.C. (a.ciulli@dundee.ac.uk). 
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Figure Legends  
Figure 1. The crystal structure of the Brd4BD2:MZ1:VHL-ElonginC-ElonginB complex. a, 
Overall structure of Brd4BD2:MZ1:VHL-ElonginC-ElonginB in ribbon representation. Top middle, 
chemical structure of bifunctional PROTAC molecule MZ1. Top right, Fo−Fc omit map generated 
prior to ligand modelling contoured at 3.0σ around bound MZ1. b, Key residues forming the 
hydrophobic "base" of the induced Brd4BD2:VHL interface. The "WPF" shelf of Brd4BD2 and extended 
"PWPF" stack are outlined in black. The JQ1 and VH032 elements of MZ1 are labelled in yellow. c, 
Electrostatic potential map showing the charged zipper contacts between Brd4BD2 residues D381 and 
E383 with VHL residues R107 and R108. d, Electrostatic potential map showing the interaction 
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between Brd4BD2 residue E438 with VHL residue R69. The hydrogen bond between H437 of Brd4BD2 
and the PEG linker of MZ1 is also shown. Dashed lines indicate hydrogen bonds with shown distance 
in angstroms (Å). 
 
Figure 2. Brd4BD2 and VHL form a stable, cooperative complex in the presence of MZ1. a, Novel 
ligand contacts are induced by ternary complex formation. Colour strength (from white to red) 
indicates the mean enthalpic energies of individual MZ1 atoms in contacting Brd4BD2 (left) or VHL 
(right), as well as intra-ligand contacts within MZ1 (centre) in a 100 ns MD simulation. b, Inverse 
ITC titrations of VCB into MZ1 (left, representative of eight replicates) and VCB into the pre-formed 
MZ1:Brd4BD2 (right, performed in duplicate) c, Ternary complex equilibria and definition of 
cooperativities. d, ΔpKd measured for VCB with MZ1 and the indicated BET-BDs, reported as 
difference (± uncertainty), from pKd values measured as mean (± 1 s.e.m.) as described in Online 
Methods. Statistical significance of pKd values for ternary titrations compared to the corresponding 
binary titrations was assessed by two-tailed t-test assuming equal variances, and is indicated as * (p-
value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). e, Simulated fraction of ternary 
complexes based on mathematical model described in ref. 23. f, AlphaLISA intensity values titrating 
VCB against BET-BDs with MZ1. AlphaLISA intensities represent mean (± 1 s.d.) of intensity values 
from four technical replicates. The hook effect observed on these curves is due to biotinylated-VCB 
oversaturating the donor beads, resulting in a progressive decrease in signal. 
 
Figure 3. The molecular basis of MZ1-induced compact complex formation between Brd4BD2 
and VHL. a, Sequence alignment of BET bromodomains. Residues of Brd4BD2 in contact with MZ1 
and/or VHL are highlighted. b, Structural alignment of Brd2BD1 (yellow) superposed on Brd4BD2 (dark 
green) in the ternary structure with MZ1 and VHL. Key, non-conserved interacting residues are 
shown in sticks. c, ΔpKd measured for VCB with MZ1 and the indicated BET-BDs, reported as 
difference (± uncertainty), from pKd values measured as mean (± 1 s.e.m.) as described in Online 
Methods. Statistical significance of pKd values for ternary titrations compared to the corresponding 
binary titrations (in black) and for ternary titrations of WT compared to the corresponding triple-
mutant (in red) was assessed by two-tailed t-test assuming equal variances, and is indicated as * (p-
value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). d, AlphaLISA intensity values titrating 
Brd2BD1, Brd4BD2 and corresponding mutants against VCB with MZ1. AlphaLISA intensities are the 
mean (± 1 s.d.) of intensity values from four technical replicates. 
 
Figure 4. Structure-guided design and characterization of Brd4-selective degrader AT1. a, A 
vector linking VH032 to JQ1 that maintains the relative binding orientation. b, Chemical structure of 
AT1. c, ΔpKd measured for VCB with AT1 and the indicated BET-BDs, reported as difference (± 
uncertainty), from pKd values measured as mean (± 1 s.e.m.). Statistical significance of pKd values for 
ternary titrations compared to corresponding binary (black) and for ternary WT compared to 
corresponding mutant (red) was assessed by two-tailed t-test assuming equal variances. d, AlphaLISA 
intensity values titrating VCB against BET-BDs with AT1 (left) and BET-BDs against VCB with 
AT1 (right). AlphaLISA intensities are the mean (± 1 s.d.) of intensity values from four technical 
replicates. e–g, Highly selective degradation of Brd4 by AT1 in HeLa cells after 24 h. e, Protein levels 
are shown from one representative of three biological replicates, visualized by immunoblot (left) and 
quantified relative to DMSO (right). Intensity values were measured as described in Online Methods. 
Full gels are provided in Supplementary Fig. 11. f, Impact of AT1 (1 µM, 24 h) on the cellular 
proteome. Data plotted as fold change (log2) of replicate 1 vs replicate 2, for a total of 5,674 proteins 
quantified (see Online Methods). g, Quantified levels of BET proteins shown are mean (± 1 s.e.m.) 
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from two replicates relative to mean of vehicle. Statistical significance of relative protein abundance 
compared to DMSO was assessed by two-tailed t-test assuming equal variances. Statistical 
significance indicated as * (p-value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). 
 
Figure 5. Schematic model of selective PROTAC-induced target degradation. A target is 
preferentially recruited in a stable and positively cooperative ternary complex with the E3 ubiquitin 
ligase upon folding of the bifunctional probe to induce formation of specific PPIs. 
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Table 1. Thermodynamic parameters of formation of binary and ternary complexes between MZ1, VCB and BET 
bromodomains measured by isothermal titration calorimetry. 
 
Protein in 
syringe 
Species in cell Kd (nM) ∆G (kcal × mol
-
1) ∆H (kcal × mol
-1) –T∆S (kcal 
× mol-1) N  α ∆pKd 
Brd2BD1 
MZ1 
62 ± 6 –9.84 ± 0.06 –12.8 ± 0.7 3.0 ± 0.8 1.1 ± 0.1   
Brd2BD2 60 ± 3 –9.85 ± 0.03 –9.8 ± 0.3 –0.1 ± 0.3 1.2 ± 0.1   
Brd3BD1 21 ± 5 –10.2 ± 0.1 –14.7 ± 0.8 4.2 ± 0.9 1.1 ± 0.1   
Brd3BD2 13 ± 3 –10.8 ± 0.1 –14.0 ± 0.9 3.3 ± 0.7 1.05 ± 0.02   
Brd4BD1 39 ± 9 –10.1 ± 0.1 –14.7 ± 0.4 4.6 ± 0.5 0.95 ± 0.03   
Brd4BD2 15 ± 1 –10.68 ± 0.04 –10.9 ± 0.4 0.2 ± 0.4 1.08 ± 0.07   
Brd2BD1 
KEA 
69 ± 9 –9.78 ± 0.08 –14 ± 1 4 ± 1 0.83 ± 0.08   
Brd4BD2 
QVK 
22 ± 8 –10.5 ± 0.2 –12.4 ± 0.5 1.9 ± 0.2 1.0 ± 0.1   
VCBa MZ1a 66 ± 6 –9.81 ± 0.05 –7.7 ± 0.3 –2.1 ± 0.3 0.93 ± 0.04   
VCB 
MZ1:Brd2BD1 24 ± 8 –10.4 ± 0.2 –7.3 ± 0.2 –3.1 ± 0.4 1.1 ± 0.2 2.9 0.4 ± 0.2 
MZ1:Brd2BD2 28 ± 3 –10.3 ± 0.1 –10.5 ± 0.1 0.2 ± 0.2 1.07 ± 0.02 2.3 0.36 ± 0.06
MZ1:Brd3BD1 19 ± 4 –10.6 ± 0.1 –8.8 ± 0.5 –1.8 ± 0.7 1.01 ± 0.01 3.5 0.5 ± 0.1 
MZ1:Brd3BD2 7 ± 2 –11.2 ± 0.2 –6.3 ± 0.1 –4.9 ± 0.3 0.99 ± 0.04 10.7 1.0 ± 0.2 
MZ1:Brd4BD1 28 ± 6 –10.3 ± 0.1 –9.1 ± 0.9 –1 ± 1 0.97 ± 0.06 2.3 0.4 ± 0.1 
MZ1:Brd4BD2 3.7 ± 0.7 –11.5 ± 0.1 –8.9 ± 0.1 –2.6 ± 0.2 1.02 ± 0.02 17.6 1.24 ± 0.09
MZ1:Brd2BD1 KEA 12 ± 7 –10.9 ± 0.4 –5.7 ± 0.2 –5.2 ± 0.2 0.8 ± 0.1 7.9 0.8 ± 0.3 
MZ1:Brd4BD2 QVK 14.9 ± 0.1 –10.68 ± 0.03 –6.2 ± 0.3 –4.5 ± 0.3 0.9 ± 0.1 4.2 0.62 ± 0.04
 
All ITC titrations were performed at 25 °C. Values reported are the mean ± S.E.M. from two independent measurements, except for 
VCB titration into MZ1 (line a) for which values reported are the mean ± S.E.M. from eight independent measurements. 
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Online Methods 
 
Chemical synthesis: Synthesis of compounds described in this paper and their intermediates 
are described in the Supplementary Note.  
Constructs, protein expression and purification. Wild-type and mutant versions of human 
proteins VHL (UniProt accession number: P40337), ElonginC (Q15369), ElonginB 
(Q15370), Brd2 (P25440), Brd3 (Q15059) and Brd4 (O60885) were used for all protein 
expression. For expression of VBC, N-terminally His6-tagged VHL (54–213), ElonginC (17–
112) and ElonginB (1–104) were co-expressed in Escherichia coli BL21(DE3) at 24 °C for 
16 h using 3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). E. coli cells were lysed 
using a pressure cell homogenizer (Stansted Fluid Power) and lysate clarified by 
centrifugation. His6-tagged VCB was purified on a HisTrapFF affinity column (GE 
Healthcare) by elution with an imidazole gradient. The His6 tag was removed using TEV 
protease and the untagged complex dialysed into low concentration imidazole buffer. VCB 
was then flowed through the HisTrapFF column a second time, allowing impurities to bind as 
the complex eluted without binding. VCB was then additionally purified by anion exchange 
and size-exclusion chromatography using MonoQ and Superdex-75 columns (GE 
Healthcare), respectively. The final purified complex was stored in 20 mM Bis Tris, pH 7, 
150 mM sodium chloride and 1 mM dithiothreitol (DTT). Brd2BD1 (71–194), Brd2BD2 (344–
455), Brd3BD1 (24–146), Brd3BD2 (306–416), Brd4BD1 (44–178) and Brd4BD2 (333–460) as 
well as equivalent mutant constructs were expressed with an N-terminal His6 tag in E. coli 
BL21(DE3) at 18 °C for 20 h using 0.2 mM IPTG. His6-tagged BDs were purified on nickel 
Sepharose™ 6 fast flow beads (GE Healthcare) by elution with increasing concentrations of 
imidazole. For crystallography the His6-tagged BD was cleaved with TEV protease and 
dialysed into low concentration imidazole buffer. The BD was then flowed over the nickel 
beads a second time to remove impurities and protease. BDs were then additionally purified 
by size-exclusion chromatography using a Superdex-75 column. For AlphaLISA, ITC and 
ubiquitination reactions, following elution of His6-tagged BDs from the nickel beads, the BDs 
were purified by size-exclusion chromatography using a Superdex-75 column. The final 
purified proteins were stored in 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.5, 150 mM sodium chloride and 1 mM DTT. All chromatography 
purification steps were performed using Äkta FPLC purification systems (GE Healthcare) or 
glass econo-columns (Bio-Rad) at room temperature. 
Crystallography. VCB, MZ1 and Brd4BD2 were mixed as a 1:1:1 stoichiometric ternary 
complex with a final concentration of 10 mg/mL. Drops of the ternary complex were mixed 
1:1 with 13% (w/v) PEG 8000 and 0.1 M sodium citrate (pH 6.3) in the hanging-drop vapour 
diffusion format. Crystals appeared within minutes and were fully grown after one day. A 
crystal was dehydrated in a solution containing 18% (w/v) PEG 8000 for a few minutes and 
flash-cooled in liquid nitrogen using 20% 2-methyl-2,4-pentanediol in liquor solution as a 
cryoprotectant. Diffraction data were collected at Diamond Light Source beamline I04-1 
using a Pilatus 6M-F detector at a wavelength of 0.92819 Å. Indexing and integration of 
reflections was performed using XDS with the XDSGUI interface43, and scaling and merging 
with AIMLESS44 in CCP4i45.  The Wilson B factor was estimated at 47.2 Å2. To solve the 
phase problem the molecular replacement method was used with the program PHASER46 
using search models derived from the coordinates of VCB (PDB entry 1VCB26) and Brd4BD2 
(PDB entry 2OUO20). Two instances of the ternary complex were found in the asymmetric 
unit, indicating a final solvent content of 68% as calculated from the Matthews coefficient. 
The initial model was refined iteratively using REFMAC47 and COOT48. Ligand structures 
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and restraints were generated using the PRODRG server49. The MOLPROBITY server50 was 
used to validate the geometry and steric clashes in the structures; the distribution of backbone 
torsion angles in the Ramachandran plot are 98.3% in the favored region and 1.7% in the 
allowed region. The structure has been deposited in the protein data bank (PDB) with 
accession code 5T35 and data collection and refinement statistics are presented in 
Supplementary Table 1. Interfaces and contacts observed in the crystal structure were 
calculated with PISA51 and LIGPLOT52. All figures were generated using PyMOL. 
Molecular dynamics simulations. MD simulations were carried out using the NAMD 
program53 and the CHARMM 36 force field54. We attempted to derive ab initio topology and 
parameter files for MZ1 using Jaguar v. 9.0 (Schrödinger Inc., LLC, New York, NY, US). 
However, characterization of the minimized structure as a minimum by vibrational analysis 
proved unsuccessful (number of imaginary frequencies > 0) using several approaches and 
initial structures, probably due to the large number of atoms. Therefore topology and 
parameter files were generated using the CGenFF server55.  
To simulate the Brd4BD2:MZ1:VHL ternary complex in solution, the coordinates of the X-ray 
crystal structure of the complex (chains A and D) were used as starting structure for 
simulation. ElonginB and ElonginC, which are sufficiently far from the hydroxyproline 
recognition site of VHL (> 20 Å), were excluded to increase computational efficiency 
throughout the simulation. The model was solvated in a TIP3P water box with a padding of 
12 Å from the edge of the box to any protein atom. The system charges were neutralized with 
sodium or chloride ions as appropriate. The solvated system was minimized for 3,000 steps 
with all protein and MZ1 atoms restrained to eliminate residual unfavorable interactions 
between each other and the solvent, followed by another 5,000 steps with all atoms free to 
move. Heating of the system from 0 to 300 K was achieved in 100 ps (time step of 1 fs), with 
fixed protein backbone atoms to allow relaxation of the solvent. The system was 
subsequently equilibrated for 600 ps (time step of 2 fs) with all atoms free to move. The NPT 
ensemble was used during production simulation of 100 ns (time step of 2 fs). The 
temperature was controlled with a Langevin thermostat at 300 K, and the pressure with a 
Nose-Hoover Langevin piston barostat at 1 bar. A SHAKE constraint was applied to all 
bonds containing hydrogen atoms. Short-range nonbonded interactions were switched at 10 Å 
and cut off at 12 Å, and particle mesh Ewald summation was employed for long-range non-
bonded interactions.  
The trajectory was analysed using VMD v. 1.9.256 and taking snapshots every 10 ps of 
simulation, unless otherwise stated. To calculate root-mean-square deviations (RMSD) 
throughout the simulation, ternary complexes were superposed to the crystallographic 
complex using an in-house PyMOL script considering only Cα atoms of the VHL protein 
within a shell of 10 Å from MZ1. This was implemented in order to diminish the effect of 
structural rearrangements occurring far from the hydroxyproline recognition site of VHL 
during the simulation arising from the absence of ElonginB and ElonginC. Radius of gyration 
(Rg) of the ternary complex, i.e. the radius of a sphere with equivalent moment of inertia, was 
computed using Carma57 at each snapshot considering the protein backbone. Buried surface 
area (BSA) upon complex formation, i.e. the difference in surface-accessible surface area 
(SASA) between the formed complex and the unbound partners in the system, was computed 
considering all protein atoms and a spherical probe of radius 1.4 Å. Intermolecular contacts, 
i.e. pair-to-pair contacts between an amino acid in Brd4BD2 and VHL, were considered 
formed if more than five atoms of the amino acid were at a distance closer than 4.0 Å from 
the partner protein. Intermolecular contacts were computed using the Timeline plugin v. 2.3 
as implemented in VMD. Per-residue and per-atom inter- and intramolecular interaction 
energies (EvdW + electrostatic) were computed using an in-house automated routine of the NAMD 
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Energy plugin v. 1.4 as implemented in VMD. Interaction energies were estimated by adding 
the pair-wise van der Waals and electrostatic contributions between individual amino acids or 
atoms and the corresponding partner. In the case of per-atom calculations, the interaction 
energies of hydrogen atoms were added to their corresponding heavy atom. For 
intramolecular interactions analysis, MZ1 was divided into three sections (JQ1, PEG linker, 
and VH032) and pair-wise energetic contributions from the atoms of each section to the rest 
of the molecule (excluding 1–4 bonded atoms) were calculated. In order to obtain comparable 
and interpretable results, the following scaling factor and cutoff value were applied to the 
electrostatic contribution: 
if EvdW ≥ 0.1: Eelectrostatic = 0.07*Eraw electrostatics 
if |EvdW| < 0.1: Eelectrostatic = 0
 
Isothermal titration calorimetry (ITC) Titrations were performed on an ITC200 micro-
calorimeter (GE Healthcare). The titrations were all performed as reverse mode (protein in 
syringe, ligand in cell) and consisted of 19 injections of 2 µL protein solution (20 mM Bis-
tris propane, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 0.02 % DMSO, 
pH 7.4 ) at a rate of 2 sec/µL at 120 s time intervals. An initial injection of protein (0.4 µL) 
was made and discarded during data analysis. All experiments were performed at 25 ºC, 
whilst stirring at 600 rpm. PROTACs (MZ1 or AT1) were diluted from a 10 mM DMSO 
stock solution to 20 µM in buffer containing 20 mM Bis-tris propane, 150 mM NaCl, 1 mM 
tris(2-carboxyethyl)phosphine (TCEP), pH 7.4. The final DMSO concentration was 0.01 or 
0.02 %. Bromodomain (100 or 200 µM, in the syringe) was titrated into the PROTAC (10 or 
20 µM, in the cell). At the end of the titration, the excess of solution was removed from the 
cell, the syringe was washed and dried, VCB complex (84 or 168 µM, in the same buffer) 
was loaded in the syringe and titrated into the complex PROTAC:bromodomain. The 
concentration of the complex in the cell (C) after the first titration (8.4 or 16.8 µM), was 
calculated as follow:  
! = ! !! ∙ !!"##!!"## + !!"# 
where: C0 is the initial concentration of the PROTAC in the cell (20 µM), Vcell is the volume 
of the sample cell (200.12 µL) and Vinj is the volume of titrant injected during the first 
titration (38.4  µL). Titrations for the binary complex PROTAC:VCB were performed as 
follow: to the solution of PROTAC (10 or 20 µM, in the cell), buffer (38.4 µL) was added by 
means of a single ITC injection. The excess of solution was removed from the cell, the 
syringe was washed and dried, VCB complex (84 or 168 µM, in the same buffer) was loaded 
in the syringe and titrated into the diluted PROTAC solution. The data were fitted to a single 
binding site model to obtain the stoichiometry n, the dissociation constant Kd and the 
enthalpy of binding ΔH using the Microcal LLC ITC200 Origin software provided by the 
manufacturer. The reported values are the mean ± s.e.m. from independent measurements 
(eight for VCB into MZ1; seven for VCB into AT1; two for each BD into VCB:PROTAC). 
Simulations of ternary complex fractions. Fractions of ternary complexes were calculated 
by applying the ternary equilibria model in the excel spreadsheet provided in ref. 23. Input 
parameters were [VHL]t = [BD]t = 40 nM; Kd (VHL) = 66 nM; Kd and α (BD) were as 
measured by ITC (Table 1). 
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Biotinylation of VCB. To biotinylate VCB the complex was mixed in a 1:1 stoichiometry 
with EZ-Link NHS-PEG4-Biotin (Thermo Scientific) and incubated at room temperature for 
1 h. To remove any unreacted NHS-biotin the sample was run over a PD-10 desalting column 
(GE Healthcare) into 20 mM HEPES, pH 7.5, 150 mM sodium chloride and 1 mM DTT. 
AlphaLISA assays. All assays were performed at room temperature and plates sealed with 
transparent film between addition of reagents. All reagents were diluted in 50 mM HEPES, 
pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine serum albumin and 0.02% (w/v) 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and each solution was 
prepared as a 5× stock and mixed into a final volume of 25 µL per well. Each protein sample 
(biotinylated VCB and His6-BD) and PROTAC were mixed and incubated for 1 h. Ni-coated 
acceptor beads were added and plates incubated another 1 h. Streptavidin-coated donor beads 
were added and plates incubated for a final 1 h. Plates were read on a PHERAstar FS (BMG 
Labtech) using an optic module with an excitation wavelength of 680 nm and emission 
wavelength of 615 nm. Within each read there was a settling time of 0.1 s, an excitation time 
of 0.3 s and an integration time of 0.6 s. For BET-BD titration experiments, VCB and 
PROTACs or Biotin-JQ1 alone were kept constant at a final concentration of 20 nM and 
His6-BD was serially diluted three-in-five from 200 nM. For VCB/Biotin-JQ1 titration 
experiments, His6-BDs and PROTACs were kept constant at a final concentration of 40 nM 
and VCB or Biotin-JQ1 was serially diluted one-in-two from 200 nM. The intensity values 
were plotted with concentration values on a log10 scale.  
Tissue culture. Human HeLa cell lines were obtained from ATCC and were kept in DMEM 
medium (Gibco) supplemented with 10% FBS (Gibco), L-glutamate (Gibco), penicillin and 
streptomycin. Cells were kept in incubator at 37 °C, 5% CO2. All cell lines were tested for 
mycoplasma contamination every month using MycoAlert™Mycoplasma detection kit 
(Lonza). 
Cell treatment and lysis. HeLa cells were seeded at 2.5×105 per well on a standard six-well 
plate. After a day, cells were treated with test compounds for the desired period of time. Cells 
were washed with PBS twice before lysis. Lysis was achieved by applying RIPA buffer 
(Sigma), supplemented with 1× protease inhibitor cocktail (Roche), Benzonase (Merck) and 
0.5 mM MgCl2 to the cells on ice. Lysate was briefly sonicated and then centrifuged at 
20,000 × g for 10 min at 4 °C. Supernatant was collected as cell extract and protein 
concentration was measured by BCA assay. The extract was snap frozen in liquid nitrogen 
for storage before being used for Western blot analysis. Cycloheximide (C7698, Sigma 
Aldrich) was used at 100 µg/mL for the indicated times. 
Western blot. Blots were probed with antibodies for Brd4 (AbCam ab128874, 1:1,000 
dilution), Brd3 (AbCam ab50818, 1:500 dilution), Brd2 (AbCam ab139690, 1:2,000 
dilution), β-actin (AbCam ab8227, 1:2,000 dilution) and cMyc (AbCam ab32072, 1:1,000 
dilution) antibodies. Blots were developed with anti-Mouse or anti-Rabbit IRDye® 800CW 
secondary antibody from Licor (1:10,000 dilution) and bands visualized using Licor Odyssey 
Sa imaging system. Image processing and band intensity quantification were done using 
Licor Image Studio software Version 5.2.5. Ubiquitination blots were probed with anti-6×His 
antibody (AbCam ab18184, 1:2,000 dilution) and then with Anti-mouse IgG, HRP-linked 
Antibody (Cell Signaling technology #7076, 1:2,000 dilution). Probed blots were visualised 
with ECL Western Blotting Substrate (Pierce #32106) on film. 
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Sample preparation for MS proteomics. HeLa cells were seeded at 2×106 on a 100mm 
plate 24 h before treatment. To treat the cells, culture medium was replaced with 12 mL of 
medium containing the test compound. After 24 h, medium was removed and cells were 
washed with 12 mL of cold PBS twice. Samples were kept on ice from this point onwards. 
Cells were lysed in 0.5 mL of 100 mM Tris pH 8.0, 4% (w/v) SDS supplemented with 
protease inhibitor cocktail (Roche). The lysate was pulse sonicated briefly and then 
centrifuged at 17,000 × g for 15 min at 4 °C. The supernatant fraction of cell extract was 
snap-frozen in liquid nitrogen and stored in −80 °C freezer before further processing. 
Sample preparation for MS proteomics. Samples were quantified using a micro BCA 
protein assay kit (Thermo Fisher Scientific) and 200µg of each sample was processed and 
digested using the Filter Aided Sample Preparation (FASP) method 58. The samples were then 
desalted using a 7 mm, 3 ml C18 SPE cartridge column (EmporeTM, 3M) and labelled with 
TMT 59 10plexTM Isobaric Label Reagent Set (Thermo Fisher Scientific) as per manufacturers 
instructions. After labelling, the peptides from the 10 samples were pooled together in equal 
proportion. The pooled sample was fractionated into 20 discrete fractions using high pH 
reverse phase chromatography 60 on a XBridge peptide BEH column (130 Å, 3.5 µm 2.1 X 
150 mm, Waters) using an Ultimate 3000 HPLC system (Thermo Scientific/Dionex). Column 
temperature was set to 20 oC. The peptides were separated using a mix of buffers A (10 mM 
ammonium formate in water, pH 10) and B (10 mM ammonium formate in 90% CH3CN, pH 
10). The peptides were eluted from the column using a flow rate of 200 µl/min and a linear 
gradient from 5% to 60% buffer B over 60 min.  The peptides eluted from the column were 
separated into 40 fractions prior to concatenation into 20 fractions based on the UV signal of 
each fraction. All the fractions were dried in a speedvac concentrator and resuspended in 10 
µl 5% formic acid, then diluted to 1% prior to MS analysis. 
nLC-MS/MS analysis. The fractions were analysed sequentially on a Q ExactiveTM HF 
Hybrid Quadrupole-OrbitrapTM Mass Spectrometer (Thermo Scientific) coupled to an 
Ultimate 3000 RSLC nano UHPLC system (Thermo Scientific) and Easyspray column (75 
µm × 50 cm, PepMap RSLC C18 column, 2 µm, 100 Å, Thermo Scientific). The peptides 
from each fraction were separated using a mix of buffer A (0.1% formic acid in MS grade 
water) and B (0.08% formic acid in 80% MS grade CH3CN). The peptides from each fraction 
were eluted from the column using a flow rate of 300 nl/min and a linear gradient from 5% to 
40% buffer B over 122 min. The column temperature was set at 50 oC. The Q ExactiveTM HF 
Hybrid Quadrupole-OrbitrapTM Mass Spectrometer was operated in data dependent mode 
with a single MS survey scan followed by 10 sequential m/z dependant MS2 scans. The 10 
most intense precursor ions were sequencially fragmented by Higher energy Collision 
Dissociation (HCD). The MS1 isolation window was set to 0.4 Da and the resolution set 
120,000. MS2 resolution was set as 60,000. The maximum ion injection time for MS1 and 
MS2 were set at 50 msec and 200 msec, respectively. 
Peptide and protein identification. The raw ms data files for all 20 fractions were merged 
and searched against the Sprot database with taxonomy set to Homo sapiens by Proteome 
Discoverer Version 1.4 (Thermo Scientific) using the Mascot v.2.4.1 (Matrix Science) search 
engine for protein identification and TMT reporter ion quantitation. The identification was 
based on the following database search criteria: enzyme used Trypsin/P; maximum number of 
missed cleavages equal to 2; precursor mass tolerance equal to 10 ppm; fragment mass 
tolerance equal to 0.06 Da; dynamic modifications: Oxidation (M), Dioxidation (M), Acetyl 
(N-term), Gln->pyro-Glu (N-term Q), Pro->Hyp (P), Deamidation(N,Q); static modifications: 
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Carbamidomethyl (C), TMT10plex (K), TMT10plex (N-term). For protein identification the 
mascot ion score threshold was set at 30 and a minimum of 2 peptides was required. 
Peptide and protein quantitation. The ratios of TMT reporter ion abundances in MS/MS 
spectra generated by HCD from raw data sets were used for TMT quantification. Isotopic 
correction factors were applied for the batch of TMT reagents used in this experiment as per 
manufacturers recommendation. A minimum of two unique peptides was used for 
quantitation and the resultant ratios were normalized based on protein median. Quantified 
proteins were filtered if the absolute fold change difference between the two DMSO 
replicates was ≥ 1.3. 
Model construction of the multisubunit CRL2VHL–MZ1–Brd4 complex. A structural 
model of the CRL2VHL (VHL–EloC–EloB–Cul2–Rbx1) with bound MZ1–Brd4BD2 at one end 
and E2–Ubiquitin at the other end was constructed in PyMOL by aligning our Brd4BD2–
MZ1–VHL–EloC–EloB on to the quaternary structure VHL–EloC–EloB–Cul2NTD (PDB 
entry 4WQO). Cul2NTD and Cul2CTD were modelled based on the structures of Cul5NTD (PDB 
entry 2WZK) and Cul1CTD–Rbx1 (PDB entry 3RTR) and superposed onto full-length Cul1 
from PDB entry 1LDK. Finally, the Rbx1–E2–Ub arm was modelled based on the crystal 
structure of Rbx1–Ubc12~NEDD8–Cul1–Dcn1 (PDB entry 4P5O) superposed via the cullin 
subunit. 
Recombinant ubiquitination experiments and ubiquitination site identification. His6-
tagged BET-BDs (2 µM) were ubiquitinated in the presence of E1 Ube1 (19 nM), E2 Ube2d1 
(145 nM), ubiquitin (Ubiquigent, 1 mg/mL), recombinant VHL-ElonginC-ElonginB-Cullin2-
Rbx1 complex (330 nM) and MZ1 (2 µM) standing for 24 h at room temperature in a buffer 
of 25 mM HEPES, pH 7.5, 5 mM MgCl2, 100 mM NaCl, 2 mM ATP, 0.1 mg/mL BSA and 1 
mM TCEP. Reactions were terminated by the addition of 1× NuPAGE LDS sample buffer 
(Invitrogen).  
Sample preparation for MS. Samples were run 1–2 cm into a pre-cast 4–12% Bis-Tris 
NuPAGE gel and the entire protein content of each lane excised, washed and dried. Proteins 
were reduced with 10 mM DTT and 20 mM ammonium carbonate at 56 °C for 60 min and 
then alkylated with 50 mM N-ethylmaleimide and 20 mM ammonium carbonate at room 
temperature for 30 min. Proteins were trypsinized overnight at 30 °C and the resulting 
peptides extracted and dried down.  
nLC-MS/MS analysis. Each peptide sample was reconstituted in 10 µl 5% formic acid then 
diluted to 1% prior to MS analysis. Peptide samples were injected onto a C18 PepMap 100 
(300 µm x 5 mm, Thermo Scientific) trap column with buffer A (0.1% formic acid in MS 
grade water) using an Ultimate 3000 RSLC nano UHPLC system. After a 5 min wash at 5 
µl/min the sample was then eluted onto an EasySpray PepMap RSLC C18 column (75 µm x 
50 cm, Thermo Scientific) into a LTQ Orbitrap Velos Pro via an EasySpray ion source. The 
peptides were eluted from the column using a flow rate of 300 nl/min and a linear gradient 
from 2% to 40% buffer B (0.08% formic acid in 80% MS grade CH3CN) over 124 min. The 
column temperature was set at 50 oC.  The Orbitrap Velos Pro ms system was operated in 
data dependant acquisition mode using a Top 15 method with Lockmass = 445.120024. A 
MS1 survey scan with a range of 335–1800 m/z and a resolution of 60,000 was followed by 
15 sequential MS2 scans at the normal scan rate using the LTQ Velos ion trap. The FTMS 
and ITMS AGC targets were set to 1e6 ions and 5e3 ions respectively. The FTMS and ITMS 
maximum fill times were set to 500 msec and 100 msec respectively. ITMS isolation width 
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was set at 2 Da with a normalised collision energy of 35, a default charge state of 2, an 
Activation Q of 0.250 and Activation Time of 10 msec. 
Peptide and protein identification. The resultant raw data was searched against the Sprot 
database with a taxonomy filter set to H. sapiens using the Mascot v. 2.4.1 (Matrix Science) 
search engine to identify peptides containing Lysines with εN-linked di-glycine 
modifications. Peptide mass tolerance was set to 10 ppm and the fragment mass tolerance set 
to 0.6 Da. The number of maximum miss-cleavages was set to 2. The enzyme was set to 
Trypsin/P and the following variable modifications were considered: Acetyl (N-term), 
Deamidated (NQ), Dioxidation (M), Gln->pyro-Glu (N-term Q), GlyGly (K), Oxidation (M).  
A fixed modification for Cysteine was set to N-ethylmaleimide. A mascot ion score threshold 
was set at 37 to filter non-significant peptide identifications. 
Statistical methods. No statistical methods were used to predetermine sample size. The 
experiments were not randomized, and the investigators were not blinded to allocation during 
experiments and outcome assessment. For all experiments, number of replicates (n), mean 
value, error value and P value cutoffs are described in the respective figure legends. Error 
bars are shown for all data points with replicates as a measure of variation with the group. All 
t-tests performed were two-tailed t-tests assuming equal variances. 
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Supplementary Results 
 
 
Supplementary Figure 1. Chemical structures of the PROTAC compounds used in this work. 
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Supplementary Figure 2. Analysis of the asymmetric unit of the Brd4BD2:MZ1:VCB crystal 
structure. a, Two complexes are present in the asymmetric unit. The eight protein chains (A–H) are 
shown as ribbons coloured according to average B factor per residue. Complex 1 is comprised of 
chains A–D and Complex 2 is comprised of chains E–H. b, Superposition of the two 
Brd4BD2:MZ1:VCB ternary complexes in the asymmetric unit. The complexes were superposed via 
the backbone atoms of the VHL substrate-binding domain (residues 61–153). c, Analysis of crystal 
contact imposing on the induced Brd4BD2:VHL interface in Complex 2. Arg177 from VHL in 
Complex 1 (chain D) interacts with Glu383 from Brd4BD2 in Complex 2 (chain E), resulting in two 
observable conformations of the side chain and displacing VHL residue Arg107 in Complex 2 (chain 
H) from the interface. Due to this and lower average B factors we used the Complex 1 (chains A, B, C 
and D) for all subsequent analyses. d, e, Fo−Fc omit maps (green meshes) of MZ1 prior to ligand 
modelling in Complexes 1 (d) and 2 (e) contoured at 3.0σ with a carve radius of 2.2 Å and 2Fo−Fc 
maps (blue meshes) covering residues of Brd4BD2 and VHL within 4 Å of MZ1 contoured at 1.5σ with 
a carve radius of 1.8 Å. 
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Supplementary Figure 3. Analysis and comparison of ligand binding at the Brd4BD2:MZ1:VHL 
interface. a, The Brd4BD2:MZ1:VHL interface forms a bowl shape. Overall view of MZ1 and the 
induced interacting proteins. Brd4BD2 and VHL are shown as surfaces coloured according to 
electrostatic potential and the underlying ribbon illustrating secondary structure. MZ1 sits on the 
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hydrophobic base (white surface) of the bowl and is surrounded by the binding sites of Brd4BD2 and 
VHL and two complementary electrostatic arms forming the induced protein-protein interactions (Fig. 
1c,d). b, Structure of HIF-1α (dark purple) with VHL (PDB entry 1LM8; teal) reveals contacts made 
by HIF-1α residues Asp569 and Asp571 with VHL residues Arg108 and Arg107, respectively. c, 
Ternary structure of Brd4BD2 (green), MZ1 (yellow carbons) and VHL reveals similar contacts made 
by Brd4BD2 residues Asp381 and Glu383 with the same VHL residues. d, Structure of diacetylated 
histone 4 tail (H4K5acK8ac; orange sticks) bound to Brd4BD1 (PDB entry 3UVW; not shown) 
superposed with Brd4BD2 from the ternary structure (green surface). e. Ternary structure of Brd4BD2, 
MZ1 and VHL reveals that VHL does not make contacts with Brd4BD2 that are similar to those 
observed made by the bound histone tail. The PEG linker of MZ1 traces a similar line to the peptide 
backbone of histone 4 between residues Gly4 and Gly7. f, Superposition of JQ1 (purple carbons) 
bound in Brd2BD2 (PDB entry 3ONI; not shown) with MZ1 (yellow carbons) bound in Brd4BD2 (green 
surface). g, Superposition of VH032 (orange carbons) bound in VHL (PDB entry 4W9H; teal surface) 
with MZ1 (yellow carbons). 
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Supplementary Figure 4. Comparison of protein-ligand interactions involving PEG linkers of 
MZ1 and MT1. a,b, Structure of MZ1 (yellow sticks) bound to Brd4BD2 (green) from Complex 1 (a, 
chain A) and Complex 2 (b, chain E) and VHL (teal). A hydrogen bond (black dashes) between 
His437 of Brd4BD2 from Complex 1 and the proximal ether oxygen to JQ1 in MZ1 is shown. c,d, 
Structure of MT1 (PDB entry 5JWM; yellow sticks) bound to Brd4BD2 (green) from chain A (c) and 
chain B (d). Hydrogen bonds (black dashes) between His437 and the ether oxygens of MT1 are 
shown. The complementary Brd4BD2 molecule in the MT1-induced dimer is shown in grey in each 
case. 
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Supplementary Figure 5. Computational study of the intermolecular interactions in the 
Brd4BD2:MZ1:VHL complex. a, Radius of gyration (Rg), buried surface area (BSA) of the PPI and 
root-mean-square deviation (RMSD) for the 100 ns MD simulation of the complex starting from the 
crystal structure. b, Brd4BD2 and VHL maintain an extensive interface throughout the MD simulation. 
Residues of Brd4BD2 are plotted according to the proportion of the time during the 100 ns of the 
simulation they spend making an intermolecular contact with VHL. Residues selected for side-
directed mutagenesis are colored distinctly. c, Persistence of individual protein–protein interaction 
contacts in the Brd4BD2:MZ1:VHL complex along the MD simulation. For the sake of clarity, value 
shown is the mean averaged over 5 ns. d, Superposition of MD simulations (light green and blue) at 
99.88 ns with Brd4BD2:MZ1:VHL crystal structure (dark green and teal) through Cα atoms of VHL. e, 
f, Per-residue intermolecular interaction energies derived from MD simulations for Brd4BD2 (e) or 
VHL (f) residues contacting MZ1 (yellow) and VHL (cyan) or Brd4BD2 (green), respectively. Energies 
are the mean (± 1 s.d.) of energy values calculated as described in Online Methods from one MD run 
of 100 ns and collected every 10 ps. 
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ITC titrations for binary complex MZ1:protein 
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ITC titrations for ternary complex VCB:MZ1:BD 
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MZ1: Brd2BD1 (KEA) MZ1: Brd4BD2 (QVK)  
Supplementary Figure 6. Representative ITC titrations to form binary and ternary complexes. 
Binary complexes: MZ1 (20 µM in the cell), and BET BD (200 µM in the syringe). For VCB titration, 
MZ1 (16.8 µM in the cell), and VCB (168 µM) in the syringe. Ternary complexes: MZ1:BD (16.8 
µM) in the cell, and VCB (168 µM) in the syringe. All titrations were performed at 25 °C.  
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Supplementary Figure 7. Analysis of binary and ternary complex formation by AlphaLISA. a, 
AlphaLISA intensity values titrating Brd4BD2 against VCB with MZ1 (green) or cisMZ1 (black 
circles). b, AlphaLISA intensity values titrating each BET-BD against VCB with MZ1. c, e, g, 
AlphaLISA intensity values titrating VCB against BET-BDs with MZ2 (c), MZ3 (e), and MZ4 (g). d, 
f, h, AlphaLISA intensity values titrating each BET-BD against VCB with MZ2 (d), MZ3 (f) and 
MZ4 (h). i, AlphaLISA intensity values titrating wild-type and mutant BET-BDs against VCB with 
MZ2. AlphaLISA intensities are the mean (± 1 s.d.) of intensity values from four technical replicates.  
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ITC titrations for binary complex AT1:protein 
   
Brd2BD1 Brd3BD1 Brd4BD1 
   
Brd2BD2 Brd3BD2 Brd4BD2 
   
Brd2BD1 (KEA) Brd4BD2 (QVK) VCB  
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ITC titrations for ternary complex VCB:AT1:BD 
   
AT1:Brd2BD1 AT1:Brd3BD1 AT1:Brd4BD1 
   
AT1:Brd2BD2 AT1:Brd3BD2 AT1:Brd4BD2 
  
 
AT1:Brd2BD1 (KEA) AT1:Brd4BD2 (QVK)  
Supplementary Figure 8. Representative ITC titrations to form binary and ternary complexes. 
Binary complexes: AT1 (20 µM in the cell), and BET BD (200 µM in the syringe). For VCB titration, 
AT1 (16.8 µM in the cell), VCB (168 µM) in the syringe. Ternary complexes: AT1:BD (16.8 µM) in 
the cell, VCB (168 µM) in the syringe. All titrations were performed at 25 °C.  
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Supplementary Figure 9. Analysis of ternary complex recruitment and cellular BET protein 
degradation by AT1-6. a, d, g, j, m, p, Selective intracellular degradation of Brd4 by MZ1 (Ref. 7) 
(a), AT2 (d), AT3 (g), AT4 (j), AT5 (m) and AT6 (p) in HeLa cells treated with indicated 
concentrations of corresponding compound. Protein levels are shown from one representative of three 
biological replicates, visualised by immunoblot (left) and quantified relative to DMSO control (right). 
b, e, h, k, n, AlphaLISA intensity values titrating VCB against BET-BDs with AT2 (b), AT3 (e), AT4 
(h), AT5 (k) and AT6 (n). c, f, i, l, o, AlphaLISA intensity values titrating each BET-BD against VCB 
with, AT2 (c), AT3 (f), AT4 (i), AT5 (l) and AT6 (o). Western blot intensity values were quantified as 
described in Online Methods. AlphaLISA intensities are the mean (± 1 s.d.) of intensity values from 
four technical replicates. 
 
 14 
 
Supplementary Figure 10. Cycloheximide (CHX) chase assay to compare BET protein turnover 
in cells. HeLa cell protein synthesis was blocked with 100 µg/mL CHX for the given period of time 
from zero to 24 hours. After the treatment, 30 µg protein extracts from cells were analysed by 
Western blot (left) probing for BET proteins, cMyc or β-actin to examine depletion rate of these 
proteins in cells and quantified relative to DMSO control (right). The CHX treatment was effective as 
levels of cMyc, which is known to have short half-life, were depleted within two hours. All BET 
proteins were depleted in cells at slower rates compared to cMyc with no distinct differences between 
Brd2, Brd3 or Brd4. Such observation does not match with the preferential depletion of Brd4 induced 
by MZ1 and other PROTAC molecules, suggesting that such preference is not due to differences in 
native protein synthesis or turnover rate. Intensity values were quantified as described in Online 
Methods and are calculated from one biological replicate. 
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Supplementary Figure 11. Full uncut gel images of western blots data. 
 
  
 17 
 
 
Supplementary Figure 12. Model of CRL2VHL–MZ1–Brd4BD2, in vitro ubiquitination and 
identification of target lysines. a, Model of CRL2VHL bound to MZ1–Brd4BD2. Solvent-exposed 
lysines of Brd4BD2 are highlighted as spheres and labelled. b, In vitro ubiquitination of Brd4BD2 by 
CRL2VHL in the presence of increasing concentrations of MZ1.  Western blot probing for His6 
purification tag was used to visualize target protein levels.  c,d, Ubiquitination sites identified in vitro 
 18 
by mass spectrometry, highlighted in green in the sequence alignment. Residue K346 is located at the 
N-terminal tail of Brd4BD2 (as indicated in a) and is not visible in our co-crystal structure.  
 
Supplementary Data Set 1:  
Proteomic analysis of relative protein abundance in HeLa cells. Results are graphically 
represented in Figure 4f,g.  See file “Supplementary Data Set 1.xls”  
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Supplementary Table 1. Data collection and refinement statistics (molecular 
replacement) 
 Brd4BD2:MZ1:pVHL-ElonginC-ElonginB 
(5T35) 
Data collection  
Space group P32 
Cell dimensions    
    a, b, c (Å) 102.3, 102.3, 144.3 
    α, β, γ (°)  90, 90, 120 
Resolution (Å) 48.2–2.7 (2.79–2.70)* 
Rmerge 7.9 (66.0) 
I/σ(I) 14.7 (2.1) 
CC1/2 99.8 (57.1) 
Completeness (%) 99.7 (99.3) 
Redundancy 4.2 (3.7) 
  
Refinement  
Resolution (Å) 48.2–2.7 
No. reflections 44157 (3322) 
Rwork  20.6 (32.3) 
Rfree 23.1 (37.4) 
No. atoms  
    Protein 7191 
    Ligand 138 
    Water 86 
B factors  
    Protein 63.7 
    Ligand 42.5 
    Water 39.7 
R.m.s. deviations  
    Bond lengths (Å) 0.007 
    Bond angles (°) 1.14 
* Highest-resolution shell is shown in parentheses. 
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Supplementary Table 2. Breakdown of buried surface areas in the ternary complexes 
ligase:ligand:target. 
Buried surface 
areas in ternary 
complexes (Å2) 
VHL: 
MZ1: 
Brd4BD2 a 
CRBN: 
lenalidomide: 
CK1α  b 
CRBN: 
CC-885: 
GSPT1 c 
Ligase:target PPIs 688 1164 1263 
Ligase:ligand 957 468 666 
Target:ligand 976 198 461 
Total 2621 1830 2390 
Buried surface areas were calculated with PISA (see ref. 52). The more extensive 
protein:ligand buried surface areas for our PROTAC ternary structure are consistent with the 
larger bifunctional nature of the compound MZ1 compared to the phthalimide-based ligands. 
These are in part compensated by the larger PPI contact areas in the CRBN examples, 
resulting in all cases in extensive total buried surface areas of > 1800 Å2, as expected for a 
productive protein-protein interaction. 
a crystal structure from this study. 
b crystal structure from ref. 2 (PDB entry 5FQD). 
c crystal structure from ref. 3 (PDB code 5HXB). 
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Supplementary Table 3. Thermodynamic parameters of formation of binary and ternary complexes between AT1, VCB and BET 
bromodomains measured by isothermal titration calorimetry. 
 
Protein in 
syringe 
Species in cell Kd (nM) ΔG (kcal × mol-1) ΔH (kcal × mol-1) –TΔS (kcal × mol-1) N  α ΔpKd 
Brd2BD1 
AT1 
111 ± 14 –9.49 ± 0.07 –16.2 ± 0.6 6.7 ± 0.7 0.858 ± 0.004   
Brd2BD2 94 ± 9 –9.59 ± 0.06 –8.2 ± 0.1 –1.43 ± 0.07 0.81 ± 0.03   
Brd3BD1 35 ± 3 –10.18 ± 0.05 –18.4 ± 0.1 8.2 ± 0.2 0.68 ± 0.02   
Brd3BD2 39 ± 8 –10.1 ± 0.1 –12.73 ± 0.04 2.61 ± 0.09 0.701 ± 0.006   
Brd4BD1 75 ± 23 –9.8 ± 0.2 –18.4 ± 0.7 8.7 ± 0.5 0.73 ± 0.03   
Brd4BD2 44 ± 8  –10.2 ± 0.1 –9.8 ± 0.9  0 ± 1 0.69 ± 0.02   
Brd2BD1 
KEA 
35 ± 4 –10.18 ± 0.06 –15 ± 1 5 ± 1  0.9 ± 0.2   
Brd4BD2 
QVK 
38.8 ± 0.5 –10.11 ± 0.01 –10.9 ± 0.9 0.8 ± 0.9 0.69 ± 0.01   
VCBa AT1a 335 ± 30 –8.85 ± 0.06 –6.7 ± 0.4 –2.2 ± 0.5 0.81 ± 0.04   
VCB 
AT1:Brd2BD1 280 ± 120 –9.0 ± 0.3 –2.61 ± 0.05 –6.4 ± 0.3 0.88 ± 0.07 1.4 0.1 ± 0.2  
AT1:Brd2BD2 78 ± 6 –9.70 ± 0.05 –7.2 ± 0.6 –2.5 ± 0.5 0.732 ± 0.003 4.1 0.61 ± 0.05 
AT1:Brd3BD1 207 ± 2 –9.12 ± 0.01 –4.38 ± 0.03 –4.75 ± 0.02 0.709 ± 0.006 1.5 0.19 ± 0.04 
AT1:Brd3BD2 79 ± 21 –9.7 ± 0.2 –4.7 ± 0.3 –4.0 ± 0.4 0.723 ± 0.001 4.3 0.6 ± 0.1 
AT1:Brd4BD1 390 ± 150 –8.8 ± 0.2 –2.2 ± 0.3 –6.57 ± 0.04 0.68 ± 0.05 1.0 –0.1 ± 0.2 
AT1:Brd4BD2 46 ± 6 –11.01 ± 0.07 –6.9 ± 0.6 –3.1 ± 0.7 0.68 ± 0.03 7.0 0.84 ± 0.07 
AT1:Brd2BD1 KEA 52 ± 18 –10.0 ± 0.2 –5.2 ± 0.2 –5 ± 1 0.9 ± 0.2 7.0 0.8 ± 0.2 
AT1:Brd4BD2 QVK 160 ± 40 –9.3 ± 0.1 –6.2 ± 0.9 –3 ± 1 0.70 ± 0.06 2.0 0.3 ± 0.1 
All ITC titrations were performed at 25 °C. Values reported are the mean ± s.e.m. from two independent measurements, except for VCB titration 
into AT1 (line a) for which values reported are the mean ± s.e.m. from seven independent measurements. 
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CHEMISTRY 4 
 5 
 6 
General information 7 
All chemicals, unless otherwise stated, were commercially available and used without 8 
further purification. Enantiopure (+)-JQ1 was purchased from Medchemexpress LLC, 9 
Princeton, USA and deprotected to the free acid (+)-JQ1-COOH as previously described.1,2 10 
MZ1, MZ2 and MZ3 were synthesized as previously described.1 All reactions were carried 11 
out in oven- or flame-dried glassware under nitrogen atmosphere. Normal phase TLC was 12 
carried out on pre-coated silica plates (Kieselgel 60 F254, BDH) with visualization via UV light 13 
(UV 254/365 nm) and/or basic potassium permanganate solution. All commercially available 14 
reagents were used as received. Reactions were magnetically stirred; commercially available 15 
anhydrous solvents were used. Flash column chromatography (FCC) was performed using a 16 
Teledyne Isco Combiflash Rf or Rf200i, prepacked columns RediSep Rf Normal Phase 17 
Disposable Columns were used. NMR spectra were recorded on a Bruker Ascend 400. 18 
Chemical shifts are quoted in ppm and referenced to the residual solvent signals: 1H δ = 7.26 19 
(CDCl3), 13C δ = 77.16 (CDCl3); 1H δ = 3.31 (MeOD), 13C δ = 49.15 (MeOD); signal splitting 20 
patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad 21 
(br), exchangeable hydrogen with deuterium (exch) or a combination thereof. Coupling 22 
constants (JH-H) are measured in Hz. High Resolution Mass Spectra (HRMS) were recorded on 23 
a Bruker microTOF. Low resolution MS and analytical HPLC traces were recorded on an 24 
Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 25 
quadrupole LC/MS, connected to an Agilent diode array detector. The column used was a 26 
Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle size) and the compounds were 27 
eluted with a gradient of 5−95% acetonitrile/water + 0.1% ammonia (referred in the text as 28 
“basic method”) or a gradient of 5−95% acetonitrile/water + 0.1 formic acid (“acidic 29 
method”).  30 
Preparative HPLC was performed on a Gilson Preparative HPLC System with a Waters X-31 
Bridge C18 column (100 mm x 19 mm; 5 μm particle size) and a gradient of 5 % to 95 % 32 
acetonitrile in water over 10 minutes, flow 25 mL/min, with 0.1 % ammonia in the aqueous 33 
phase. 34 
 35 
Abbreviations used: DCM for dichloromethane, EtOAc for ethyl acetate, Et2O for diethyl 36 
ether, DMSO for dimethyl sulfoxide, DIPEA for N,N-diisopropylethylamine, MeOH for 37 
methanol, TEA for triethylamine, DMF for N,N-dimethylformamide, HATU for 1-38 
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 39 
hexafluorophosphate, HOAT for 1-hydroxy-7-azabenzotriazole, DBU for 1,8-40 
diazabicyclo[5.4.0]undec-7-ene, TIPS for triisopropylsilane, TFA for trifluoroacetic acid. 41 
 42 
  43 
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Synthesis of linkers 44 
 45 
 46 
Scheme 1. Reagents and conditions: i) N-(3-Bromopropyl)phthalimide , NaH in DMF 0 °C to r.t., 75%; ii) H2 (balloon), Pd/C 10% dry, in 47 
MeOH, 99%; iii) mesylchloride, triethylamine in DCM, 0 °C, 95%; iv) 2-azidoethyl 4-methylbenzenesulfonate, triethylamine in DCM, 0 °C to 48 
r.t.; v) tosylchloride, triethylamine in DCM, 0 °C to rt, 25% over two steps.  49 
 50 
 51 
Synthesis of PROTACs AT1–6 52 
 53 
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4: Y = CH2-O-(CH2)2
5: Y = O-(CH2)3
6: Y = O-(CH2)2-O-CH2
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 54 
 55 
Scheme 2. Reagents and conditions: i) HCl 2M in dioxane/DCM 1:1, r.t., 99%; Fmoc-S-trityl-L-penicillamine, HATU, HOAT, DIPEA in DMF, 56 
r.t.; iii) Piperidine 20% in DCM, r.t., 75% over two steps; iv) acetic anhydride, triethylamine in DCM 0 °C to r.t., 98%; v) TFA- TIPS 5% in 57 
DCM, r.t., 79%; vi) Linker-OMs or Linker-OTs or Linker-Br , DBU, in DMF 0 °C to r.t.,70-82%; vii) if X = N3: H2 (balloon), Pd/C 10%, in MeOH, 58 
99%; viii) if X = NPhtal: Hydrazine hydrate in ethanol, 70 °C, 60-68%; (+)-JQ1-COOH, HATU, HOAT, DIPEA in DMF, r.t. 33-70%.  59 
 60 
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Synthetic methods for the preparation of PROTAC MZ4 61 
 62 
(2S,4R)-1-((S)-2-(2-(2-(2-azidoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-63 
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (27) 64 
 65 
 66 
 67 
Prepared as previously described.1 Obtained 41.1 mg, 68% yield.  MS analysis: C28H39N7O6S 68 
expected 601.3, found 602.3 [M+H+]. 69 
1H-NMR (CDCl3, 400 MHz) δ: 8.68 (s, 1H), 7.38-7.33 (m, 5H), 7.24 (d, J = 8.5 Hz, 1H), 4.75 (t, J 70 
= 7.9 Hz, 1H), 4.59-4.54 (m, 2H), 4.48 (d, J = 8.6 Hz, 1H), 4.33 (dd, J = 14.9 Hz, J = 5.2 Hz, 1H) 71 
4.12-4.09 (m, 1H), 4.06-3.96 (m, 2H), 3.70-3.66 (m, 6H), 3.61 (dd, J = 11.4 Hz, J = 3.7 Hz, 1H), 72 
3.38-3.41 (m, 2H), 2.89 (br s, 1H), 2.63-2.58 (m, 1H), 2.52 (s, 3H), 2.08-2.13 (m, 1H), 0.95 (s, 73 
9H).  74 
13C-NMR (CDCl3, 101 MHz) δ: 171.6, 170.7, 170.6, 150.7, 138.4, 130.4, 129.7, 128.6, 128.4, 75 
127.6, 71.2, 70.5, 70.3, 70.2, 67.2, 58.5, 57.3, 56.8, 50.7, 43.4, 35.8, 34.9, 26.5, 16.0  76 
 77 
(2S,4R)-1-((S)-2-(tert-butyl)-14-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-78 
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,13-dioxo-6,9-dioxa-3,12-diazatetradecanoyl)-4-79 
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MZ4)  80 
 81 
 82 
 83 
Prepared as previously described from azide 27 (ref. 1). Yield: 22.2 mg (66 %); HRMS 84 
analysis: C46H57N9ClO7SS expected 957.3505, found 958.3498 [M+H+].    85 
1H-NMR (CDCl3, 400 MHz) δ: 8.65 (s, 1H), 9.30-8.325 (m, 2H), 7.63 (d, J = 10.0 Hz, 1H), 7.36 86 
(d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.02 (d, J = 8.0 Hz, 2H), 87 
4.94-4.86 (m, 2H), 4.63-4.57 (m, 2H), 4.21 (d, J = 5.8 Hz, 2H), 4.07-3.81 (m, 5H), 3.72-3.52 (m, 88 
7H), 3.44 (dd, J = 15.9 Hz, J = 3.0 Hz, 1H), 3.13-3.08 (m, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.39-89 
2.35 (m, 4H), 2.27-2.20 (m, 1H) 1.66 (s, 3H), 1.09 (s, 9 H).  90 
13C-NMR (CDCl3, 101 MHz) δ: 172.1, 171.1, 170.6, 170.4, 163.3, 156.2, 150.2, 149.9, 148.4, 91 
138.5, 136.9, 136.7, 131.9, 131.6, 131.4, 131.3, 131.2, 130.2, 130.1, 129, 128.8, 127.7, 71.5, 92 
70.4, 70.3, 69.8, 59.3, 57.5, 56.5, 53.9, 42.7, 39.7, 38.3, 37.2, 36.3, 26.6, 16.2, 14.5, 13.3, 93 
11.8. 94 
  95 
S4 
 
Synthetic methods for the preparation of PROTACs 1–6 96 
 97 
(2S,4R)-1-((R)-2-amino-3-methyl-3-(tritylthio)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-98 
5-yl)benzyl)pyrrolidine-2-carboxamide (12) 99 
 100 
 101 
 102 
To a solution of 10 (ref. 3)  (418 mg, 1 mmol) in DCM/MeOH 9:1 (2.5 mL), 4N HCl in dioxane 103 
(2.5 mL) was added and mixture was stirred for 4 hours at room temperature. Volatiles were 104 
removed under vacuum, the residue was dissolved in water and freeze-dried to afford 105 
(2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-ium chloride 106 
(350 mg, 99%) as a light yellow powder which was used without any further purification.  107 
To a solution of Fmoc-S-trityl-L-penicillamine (500 mg, 0.80 mmol) in DMF (2 mL), HATU 108 
(304 mg, 0.80 mmol) and HOAT (108 mg, 0.80 mmol) were added, followed by DIPEA (250 109 
µL, 1.2 mmol). The bright yellow solution was then added to a mixture of (2S,4R)-4-hydroxy-110 
2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-ium chloride (281 mg, 0.80 mmol) 111 
and DIPEA (250 µL, 1.2 mmol) in DMF (3 mL). After 2 hours complete conversion of the 112 
starting materials was observed by HPLC-MS (basic method), water was added (10 mL) and 113 
the mixture was extracted with AcOEt (3X 25 mL). The organic phase was washed with brine 114 
(10 mL) and dried over anhydrous MgSO4. Solvents were removed under vacuum to afford 115 
compound 11 which was dissolved in DCM (4 mL). Piperidine (800 µL ~ 8 mmol) was added 116 
and the reaction mixture was stirred for 1 hour. Volatiles were removed under vacuum and 117 
the crude was purified by FCC (from 5 to 15 % of 0.7 M NH3 in MeOH in DCM) to afford the 118 
title compound 12 as a white solid (414 mg, 75% yield). MS analysis: C40H42N4O5S2 expected 119 
690.3, found 691.2 [M+H+].   120 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.90 (s, 1H), 7.63-7.60 (m, 6H), 7.40-7.33 (m, 4H), 7.31-121 
7.29 (m, 6H), 7.24-7.19 (m, 3H), 4.46 (t, J = 8.2 Hz, 1H), 4.37 (br s, 1H), 4.31 (m, 2H), 3.35 (s, 122 
1H), 3.24 (dd, J = 11.1 Hz, J = 4.1 Hz, 1H), 3.07-3.04 (m, 1H), 2.70 (s, 1H), 2.47 (s, 3H), 2.16-123 
2.11 (m, 1H), 1.99-1.92 (m, 1H), 1.26 (s, 3H), 1.19 (s, 3H).  124 
13C-NMR (101 MHz, CD3OD , 25 °C) δ: 172.9, 171.4, 151.5, 147.7, 144.9, 138.7, 132.0, 129.7, 125 
129.0, 127.5, 127.4, 126.5, 69.3, 67.7, 59.4, 57.6, 57.3, 56.7, 42.1, 37.4, 24.6, 24.1, 14.4. 126 
  127 
S5 
 
(2S,4R)-1-((R)-2-acetamido-3-methyl-3-(tritylthio)butanoyl)-4-hydroxy-N-(4-(4-128 
methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (13) 129 
 130 
 131 
 132 
To a solution of 12 (214 mg, 0.31 mmol) in DCM (2 mL) at 0 °C, TEA (50 µL, 0.35 mmol) and 133 
acetic anhydride (30 µL, 0.32 mmol) were added. The mixture was let to react at room 134 
temperature for 2 hours. The mixture was diluted with DCM (10 mL), washed with water (2 135 
mL) and brine (2 mL), dried over MgSO4 and the solvent was removed under reduced 136 
pressure to afford the title compound 13 (222 mg, 98% yield) which was used without 137 
further purification. MS analysis: C42H44N4O4S2 expected 732.3, found 733.3 [M+H+].   138 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 8.71 (s, 1H), 7.52-7.49 (m, 6H), 7.39-7.31 (m, 3H),  7.25-139 
7.20 (m, 11H), 6.25 (d, J = 5.2 Hz, 1H), 4.64 (t, J = 8.1 Hz, 1H), 4.37 (br s, 1H), 4.31-4.18 (m, 140 
2H), 3.61 (d, J = 5.3 Hz, 1H), 3.52-3.49 (m, 1H), 3.30-3.29 (m, 1H), 3.22 (dd, J = 11.5Hz, J = 3.6 141 
Hz, 1H), 2.52 (s, 3H), 2.36-2.30 (m, 1H), 2.16-2.11 (m, 1H), 1.95 (s, 3H), 1.76 (br s, 1H), 1.18 142 
(s, 3H),  0.97 (s, 3H).  143 
13C-NMR (101 MHz, CDCl3, 25 °C) δ: 170.7, 170.5, 170.3, 150.3, 148.5, 144.2, 138.2, 131.7, 144 
130.8, 129.7, 129.6, 129.4, 127.9, 127.0, 77.2, 70.1, 68.5, 58.5, 57.1, 56.6, 53.6, 42.8, 36.4, 145 
26.1, 25.4, 22.9, 16.2. 146 
  147 
S6 
 
(2S,4R)-1-((R)-2-acetamido-3-mercapto-3-methylbutanoyl)-4-hydroxy-N-(4-(4-148 
methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (14) 149 
 150 
 151 
 152 
Compound 13 (114 mg, 0.16 mmol) was dissolved in 3.8 mL of DCM. TIPS (0.2 mL) and TFA 153 
(0.2 mL) were added, and the yellow mixture was let to react at room temperature for 2 h. 154 
HPLC analysis (acidic method) showed complete conversion of the starting material. 155 
Volatiles were removed and the crude was dissolved in MeOH, filtered and purified by 156 
preparative HPLC and freeze-dried to give pure compound 14 as white solid (62 mg, 79% 157 
yield). MS analysis: C23H30N4O4S2 expected 490.2, found 491.1 [M+H+].   158 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 8.68 (s, 1H), 7.39-7.33 (m, 4H), 7.20-7.17 (m, 1H), 6.55 (d, 159 
1H), 4.68 (t, J = 8.0 Hz, 1H), 4.59-4.52 (m, 3H), 4.35 (dd, J = 14.9 Hz, J = 5.2 Hz, 1H), 4.19-4.16 160 
(m, 1H), 3.70 (dd, J = 11.2 Hz, J = 3.6 Hz, 1H), 3.15 (br s, 1H), 2.29 (br s, 1H), 2.52 (s, 3H), 161 
2.48-2.42 (m, 1H), 2.20-2.15 (m,  1H), 2.01 (s, 3H), 1.36 (s, 3H), 1.31 (s, 3H). 162 
13C-NMR (101 MHz, CDCl3, 25 °C) δ: 170.9, 170.7, 170.6, 150.4, 148.6, 137.9, 131.5, 131.1, 163 
129.6, 128.1, 70.1, 58.9, 57.5, 56.6, 46.1, 43.3, 36.5, 30.7, 28.7, 23.0, 16.1. 164 
 165 
2-(3-(3-(benzyloxy)propoxy)propyl)isoindoline-1,3-dione (7) 166 
 167 
 168 
 169 
To a suspension of NaH (60% in mineral oil, 288 mg, 7.2 mmol) in DMF (10 mL) 3-170 
(benzyloxy)-1-propanol (1.00 g, 6 mmol) was added dropwise at 0 °C. After 45 min a solution 171 
of N-(4-bromopropyl)phthalimide (2.41 g, 9 mmol) in DMF (5 mL) was added dropwise. The 172 
mixture was stirred overnight, treated with KHSO4 5% to acidic pH and poured in water 173 
(50mL). The mixture was extracted with Et2O (3 X 30 mL), the organic phase was washed 174 
with brine (10 mL) and dried over MgSO4. Solvents were removed under reduced pressure 175 
and the crude was purified by FCC (10% to 30% of EtOAc in heptane) to give the title 176 
compound 7 as a viscous oil (1.59 g, 75%). MS analysis: C21H23NO4 expected 353.2, found 177 
354.2 [M+H+].      178 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 7.84-7.82 (m, 2H), 7.71-7.69 (m, 2H), 7.33-7.27 (m, 5H), 179 
4.47 (s, 2H), 3.78 (t, J = 6.9 Hz, 2H), 3.52-3.45 (m, 6H), 1.94 (q, J = 6.5 Hz, 2H), 1.79 (q, J = 6.3 180 
Hz, 2H).  181 
  182 
S7 
 
3-(3-(1,3-dioxoisoindolin-2-yl)propoxy)propyl methanesulfonate (8) 183 
 184 
 185 
 186 
Compound 7 (1.00 g, 2.83 mmol) was dissolved in MeOH (50 mL) and a catalytic amount of 187 
Pd/C (10%) was added. The mixture was stirred under hydrogen atmosphere and TLC 188 
analysis (Heptane/EtOAc 7:3) showed complete conversion of the starting material after 3 h. 189 
The mixture was filtered through a celite pad to remove the catalyst and evaporated to 190 
dryness to give the debenzylated product as a transparent oil (745 mg, quantitative yield). A 191 
portion of the crude compound (122 mg, 0.463 mmol) was dissolved in DCM (2 mL) and 192 
treated at 0 °C with TEA (78 µL, 0.555 mmol) and mesylchloride (40 µL, 0.500 mmol). The 193 
mixture was left to react for 4 h in an ice bath, then quenched with water (1 mL) and 194 
extracted with DCM (3 X 5 mL). The organic phase was dried over MgSO4. Solvents were 195 
removed under reduced pressure and the crude mesylate 8 (155 mg, considered 196 
quantitative yield) was used without further purification.        197 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 7.85-7.83 (m, 2H), 7.72-7.70 (m, 2H), 4.29 (t, J = 6.3 Hz, 198 
2H), 3.79 (t, J = 6.8 Hz, 2H), 3.49-3.46 (m, 4H), 3.01 (s, 3H), 1.97-1.89 (m, 4H).  199 
 200 
4-(2-azidoethoxy)butyl 4-methylbenzenesulfonate (9) 201 
 202 
 203 
 204 
To a solution of 1,4-butanediol (220 µL, 2.48 mmol) in DMF (1 mL) NaH (60% in mineral oil, 205 
33 mg, 0.829 mmol) was added at 0 °C. After 45 minutes, 2-azidoethyl 4-206 
methylbenzenesulfonate4 (200 mg, 0.829 mmol) was added dropwise at 0 °C. The reaction 207 
was stirred at room temperature overnight, TLC analysis (heptane/EtOAc 1:1) showed 208 
complete conversion of the starting material. The reaction was quenched with water (0.5 209 
mL) and extracted with EtOAc (3 X 3 mL). The organic phase was dried over MgSO4. Solvents 210 
were removed under reduced pressure and the crude was dissolved in DCM (2 mL), cooled 211 
to 0 °C and treated with TEA (115 µL, 0.829 mmol) and tosylchloride (158 mg, 0.829 mmol). 212 
The mixture was stirred at room temperature for 4 h, then water (2 mL) was added and the 213 
mixture was extracted with DCM (3 x 5 mL). The organic phase was dried over MgSO4. 214 
Solvents were removed under reduced pressure and the crude was purified by FCC (from 215 
10% to 40% of EtOAc in heptane) to give the pure title compound 9 as a transparent oil (65 216 
mg, 25% yield over two steps). MS analysis: C13H19N3O4S expected 313.1, found 314.0 217 
[M+H+].      218 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 7.79 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 9.0 Hz, 2H), 4.06 (t, J = 219 
6.3 Hz, 2H), 3.57 (t, J = 3.5 Hz, 2H), 3.44 (t, J = 6.0 Hz, 2H), 3.32 (t, J = 4.9 Hz, 2H), 2.45 (s, 3H), 220 
1.78-1.73 (m, 2H), 1.64-1.61 (m, 2H). 221 
 222 
General procedure for the S-alkylation of 14 223 
S8 
 
 224 
Under nitrogen and at 0 °C, a solution of compound 14 (10 mg, 0.020 mmol) in DMF (0.5  225 
mL) was treated with DBU (3.3 µL, 0.022 mmol) followed by the alkylating reagent (0.022 226 
mmol). The reaction mixture was let to react at room temperature until complete 227 
conversion of the starting material was observed by HPLC (acidic method, 1-3 h). The 228 
reaction was cooled to 0 °C and treated with few drops of KHSO4 (5 %) to pH = 3-4. The 229 
solvent was removed under vacuum and the crude was dissolved in MeOH, filtered and 230 
purified by preparative HPLC to isolate the expected product. 231 
 232 
(2S,4R)-1-((R)-2-acetamido-3-((4-(1,3-dioxoisoindolin-2-yl)butyl)thio)-3-methylbutanoyl)-233 
4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (15) 234 
 235 
 236 
 237 
Prepared following the general procedure for the S-alkylation from compound 14 (10.0 mg, 238 
0.020 mmol) and N-(4-Bromobutyl)phthalimide (6.2 mg, 0.022 mmol). Obtained 11.3 mg, 239 
82% yield.  MS analysis: C35H41N5O6S2 expected 691.2, found 692.1 [M+H+].   240 
1H NMR (400 MHz, CDCl3, 25 °C) δ: 8.67 (s, 1H), 7.85-7.83 (m, 2H), 7.74-7.72 (m, 2H), 7.46-241 
7.43 (m, 1H), 7.37-7.31 (m, 4H), 6.51 (d, J = 8.0 Hz, 1H), 4.77-4.72 (m, 2H), 4.52-4.38 (m, 3H), 242 
4.08-4.05 (m, 1H), 3.74 (dd, J = 11.1 Hz, J = 3.8 Hz, 1H), 3.66 (t, J = 7.1 Hz, 2H) 2.60-2.48 (m, 243 
5H), 2.40-2.34 (m, 1H), 2.30-2.25 (m, 1H), 2.00 (s, 3H), 1.77-1.70 (m, 2H), 1.55-1.47 (m, 2H), 244 
1.32 (s, 3H), 1.30 (s, 3H).  245 
13C-NMR (101 MHz, CDCl3, 25 °C) δ: 171.2, 170.8, 170.5, 168.5, 150.4, 148.6, 138.2, 134.2, 246 
132.1, 131.7,131.0, 129.5, 128.2, 123.4, 70.1, 59.3, 56.9, 56.3, 48.1, 43.1, 37.4, 37.1, 28.0, 247 
27.6, 26.6, 25.8, 25.6, 23.1, 16.2.   248 
  249 
S9 
 
(2S,4R)-1-((R)-2-acetamido-3-((2-(2-azidoethoxy)ethyl)thio)-3-methylbutanoyl)-4-hydroxy-250 
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (16) 251 
 252 
 253 
 254 
Prepared following the general procedure for the S-alkylation from compound 14 (10.0 mg, 255 
0.020 mmol) and 2-(2-azidoethoxy)ethyl methanesulfonate5 (4.6 mg, 0.022 mmol). Obtained 256 
9.4 mg, 78% yield.  MS analysis: C27H37N7O5S2 expected 603.2, found 604.1 [M+H+].   257 
1H NMR (400 MHz, CDCl3, 25 °C) δ: 8.68 (s, 1H), 7.39-7.31 (m, 5H), 6.39 (d, J= 8.0 Hz, 1H), 258 
4.76-4.71 (m, 2H), 4.52 (br s, 1H), 4.45 (d, J= 5.9 Hz, 1H), 4.09-4.07 (m, 1H), 3.73 (dd, J = 11.2 259 
Hz, J = 3.8 Hz, 1H), 3.58-3.50 (m, 4H), 3.34-3.31 (m, 2H), 2.76-2.68 (m, 2H), 2.51 (s, 3H), 2.43-260 
2.38 (m, 1H), 2.27-2.23 (m, 1H), 2.00 (s, 3H), 1.32 (s, 3H), 1.29 (s, 3H).  261 
13C-NMR (101 MHz, CDCl3, 25 °C) δ: 170.8, 170.7, 170.4, 150.3, 148.5, 138.1, 131.6, 131.0, 262 
129.5, 128.1, 70.4, 70.1, 69.8, 59.0, 56.7, 56.3, 56.2, 50.6, 48.5, 47.8, 43.1, 42.9, 36.8, 29.6, 263 
28.2, 25.7, 25.6, 23.0, 16.1. 264 
 265 
(2S,4R)-1-((R)-2-acetamido-3-((6-aminohexyl)thio)-3-methylbutanoyl)-4-hydroxy-N-(4-(4-266 
methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (23) 267 
 268 
 269 
 270 
Prepared following the general procedure for the S-alkylation from 14 (10.0 mg, 0.020 271 
mmol) and N-(4-Bromohexyl)phthalimide (6.6 mg, 0.022 mmol), obtaining 11.5 mg (80% 272 
yield) of 17.  MS analysis: C37H45N5O6S2 expected 719.3, found 720.3 [M+H+]. The alkylated 273 
product 17 was then dissolved in ethanol (0.5 mL) and treated with hydrazine monohydrate 274 
(24 µL, 0.32 mmol) at 60 °C for two hours. The reaction mixture was cooled to room 275 
temperature, filtered and purified by preparative HPLC to give the expected amine 23 (6.4 276 
mg, 68% yield). MS analysis: C29H43N5O4S2 expected 589.3, found 590.2 [M+H+].    277 
1H NMR (400 MHz, CD3OD, 25 °C) δ: 8.88 (s, 1H), 7.46-7.41 (m, 4H), 4.92 (s, 1H), 4.58 (t, J = 278 
8.3 Hz 1H), 4.52-4.38 (m, 3H), 3.93-3.84 (m, 1H), 3.85 (dd, J = 10.8 Hz, J = 4.0 Hz, 1H), 2.64 (t, 279 
J = 7.3 Hz, 2H), 2.56 (t, J = 7.4 Hz, 2H) 2.48 (s, 3H), 226-2.23 (m, 1H), 2.14-2.10 (m, 1H), 2.00 280 
(s, 3H), 1.49-1.28 (m, 16 H).  281 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.2, 171.6, 153.0, 149.2, 140.3, 133.5, 131.8, 282 
130.6, 129.2, 71.1, 61.1, 58.0, 57.3, 43.7, 42.3, 39.2, 32.8, 30.7, 30.1, 29.3, 27.6, 26.3, 25.7, 283 
22.5, 16.0. 284 
  285 
S10 
 
(2S,4R)-1-((R)-2-acetamido-3-((3-(3-aminopropoxy)propyl)thio)-3-methylbutanoyl)-4-286 
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (24) 287 
 288 
 289 
 290 
Prepared following the general procedure for S-alkylation from 14 (10.0 mg, 0.020 mmol) 291 
and 8 (7.5 mg, 0.022 mmol) to obtained compound 18 (11.0 mg, 75% yield).  MS analysis: 292 
C37H45N5O7S2 expected 735.3, found 736.3 [M+H+].  Deprotection of the amino group was 293 
performed as described above, with hydrazine (24 µL, 0.32 mmol) in ethanol (0.5 mL) at 60 294 
°C to give 5.4 mg of 24 (60% yield). MS analysis: C29H43N5O5S2 expected 605.3, found 606.2 295 
[M+H+].    296 
1H NMR (400 MHz, CD3OD, 25 °C) δ: 8.88 (s, 1H), 8.51 (br. s, 1H exch), 7.47-7.41 (m, 4H), 297 
4.94 (s, 1H), 4.58 (t, J = 8.3, 1H), 4.51-4.37 (m, 3H), 3.91-3.89 (m, 1H), 3.85 (dd, J = 10.8 Hz, J 298 
= 4.0 Hz, 1H), 3.52 (t, J = 5.7 Hz, 2H), 3.46 (t, J = 6.2 Hz, 2H), 3.04 (t, J = 7.0 Hz, 2H),  2.67-2.61 299 
(m, 2H), 2.48 (s, 3H), 226-2.24 (m, 1H), 2.14-2.08 (m, 1H), 2.00 (s, 3H),1.92-1.87 (m, 2H), 300 
1.77-1.72 (m, 2H), 1.43 (s, 3H), 1.37 (s, 3H).  301 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.1, 171.4, 169.9, 153.0, 149.2, 140.3, 133.5, 302 
131.8, 130.6, 129.2, 71.1, 69.5, 61.1, 57.9, 57.1, 43.8, 39.5, 39.2, 30.8, 28.7, 26.5, 26.2, 25.4, 303 
22.5, 16.0.  304 
  305 
(2S,4R)-1-((R)-2-acetamido-3-((4-(2-azidoethoxy)butyl)thio)-3-methylbutanoyl)-4-hydroxy-306 
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (19) 307 
 308 
 309 
 310 
Prepared following the general procedure for the S-alkylation from 14 (10.0 mg, 0.020 311 
mmol) and 9 (6.9 mg, 0.022 mmol). Obtained 9.2 mg, 73% yield.  MS analysis: C29H41N7O5S2 312 
expected 631.3, found 632.2 [M+H+].   313 
1H NMR (400 MHz, CD3OD, 25 °C) δ: 8.88 (s, 1H), 8.40 (t, J = 6.2 Hz, 1H exch), 8.14 (d, J = 8.9 314 
Hz, 1H exch), 7.46-7.41 (m, 4H), 4.94-4.92 (m, 1H), 4.58 (t, J = 8.3 Hz, 1H), 4.52-4.39 (m, 3H), 315 
3.94-3.92 (m, 1H), 3.86 (dd, J = 10.9 Hz, J = 4.0 Hz, 1H), 3.57 (t, J = 5.0 Hz, 1H), 3.44 (t, J = 6.0 316 
Hz, 1H), 3.33-3.30 (m, 3H), 2.60-2.57 (m, 2H), 2.48 (s, 3H), 2.29-2.24 (m, 1H), 2.14-2.08 (m, 317 
1H), 2.00 (s, 3H), 1.65-1.53 (m, 4H), 1.40 (s, 3H), 1.36 (s, 3H). 318 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.5, 173.3, 173.2, 171.6, 153.0, 149.2, 140.2, 133.5, 319 
131.8, 130.6, 129.3, 71.7, 71.0, 70.9, 61.2, 58.1, 57.4, 51.9, 43.8, 39.2, 30.3, 29.2, 27.4, 26.1, 320 
25.9, 22.4, 16.0.  321 
S11 
 
(2S,4R)-1-((R)-2-acetamido-3-((2-(2-(2-azidoethoxy)ethoxy)ethyl)thio)-3-methylbutanoyl)-322 
4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (20) 323 
 324 
 325 
 326 
Prepared following the general procedure for S-alkylation from 14 (10.0 mg, 0.020 mmol) 327 
and 2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate6  (5.6 mg, 0.022 mmol). Obtained 328 
9.3 mg, 72% yield.  MS analysis: C29H41N7O6S2 expected 647.3, found 648.2 [M+H+]. 329 
1H-NMR (400 MHz, CDCl3, 25 °C) δ: 8.67 (s, 1H), 7.39-7.32 (m, 5H), 6.45 (d, J = 8.0 Hz, 1H), 330 
4.75-4.71 (m, 2H), 4.50 (br s, 1H), 4.45-4.43 (m, 2H), 4.06-4.03 (m, 1H), 3.74 (dd, J = 11.1 Hz, 331 
J = 3.8 Hz, 1H), 3.34-3.50 (m, 8H), 3.36 (t, J = 5.0 Hz, 2H), 2.78-2.66 (m, 2H), 2.50 (s, 3H), 332 
2.39-2.33 (m, 1H), 2.28-2.22 (m, 1H), 1.97 (s, 3H), 1.88 (br s, 1H), 1.31 (s, 3H), 1.29 (s, 3H). 333 
13C-NMR (101 MHz, CDCl3, 25 °C) δ: 171.0, 170.7, 170.4, 150.3, 148.5, 138.2, 131.6, 130.9, 334 
129.5, 128.1, 70.6, 70.5, 70.4, 70.0, 59.1, 56.7, 56.2, 50.7, 47.8, 43.0, 37.0, 28.2, 25.6, 25.5, 335 
23.0, 16.1.  336 
 337 
(2S,4R)-1-((R)-2-acetamido-3-((6-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-338 
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)thio)-3-methylbutanoyl)-4-339 
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (1) 340 
 341 
 342 
 343 
Compound 23 (6.4 mg, 0.0108 mmol) was dissolved in DMF (0.25 mL) and added to a 344 
solution of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-345 
a][1,4]diazepin-6-yl)acetic acid (+)-JQ1-COOH (4.32 mg, 0.0108 mmol), HATU (4.1 mg, 346 
0.0108 mmol), HOAT (1.5 mg, 0.0108mmol) and DIPEA (5.5 µl, 0.0324 mmol) in DMF (0.5 347 
mL). After stirring at room temperature for 1 h, the reaction was quenched with water (0.1 348 
mL) and the mixture of water/DMF was removed under high vacuum at room temperature 349 
(overnight). The crude mixture was dissolved in MeOH, filtered and purified by preparative 350 
HPLC to give the title compound. Obtained 7.3 mg, 70% yield.  MS analysis: C48H58N9ClO5S3 351 
expected 971.3, found 972.3 [M+H+].   352 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.99 (s, 1H), 8. 43 (t, J = 5.9 Hz, 1 H exch.), 8.12 (d, J = 353 
9.4 Hz, 1H exch.), 8.07 (s, 1H exch.),  7.47-7.40 (m, 8H), 4.93-4.91 (m, 1H), 4.69-4.65 (m, 1H), 354 
4.58 (t, J = 8.3 Hz, 1H), 4.52-4.38 (m, 3H), 3.93-3.91 (m, 1H), 3.85 (dd, J = 10.8 Hz, J = 3.96 Hz, 355 
S12 
 
1H), 3.45-3.39 (m, 1H), 3.27-3.16 (m, 3H), 2.72 (s, 3H), 2.26 (t, J = 7.0 Hz, 2H),  2.49 (s, 3H), 356 
2.45 (s, 3H), 2.25-2.22 (m, 1H), 2.14-2.07 (m, 1H), 2.00 (s, 3H), 1.70 (s, 3H), 1.54-1.36 (m, 357 
14H).   358 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.2, 172.6, 171.6, 166.7, 157.1, 153.4, 152.6, 359 
148.5, 140.5, 138.4, 137.9, 133.9, 133.6, 132.3, 132.2, 131.6, 131.4, 130.6, 130.0, 129.7, 360 
129.3, 71.0, 61.2, 58.1, 57.4, 55.2, 43.7, 40.5, 39.2, 38.7, 30.7, 30.5, 30.0, 29.3, 27.7, 26.2, 361 
25.9, 22.5, 15.7, 14.6, 13.1, 11.7. 362 
 363 
(2S,4R)-1-((R)-2-acetamido-3-((4-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-364 
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)butyl)thio)-3-methylbutanoyl)-4-365 
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (2) 366 
 367 
 368 
 369 
Compound 15 (11.3 mg, 0.0163 mmol) was dissolved in ethanol (0.5 mL) and treated with 370 
hydrazine monohydrate (24 µL, 0.32 mmol) at 60 °C for 2 h. The reaction mixture was 371 
cooled to room temperature, filtered and dried under vacuum to obtain compound 21. The 372 
crude was made to react with (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-373 
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid (+)-JQ1-COOH (6.1 mg, 0.015 mmol), 374 
HATU (6.0 mg, 0.015 mmol), HOAT (2.0 mg, 0.015 mmol) and DIPEA (8.0 µl, 0.045 mmol). 375 
Obtained 5.0 mg, 33% yield after preparative HPLC purification.  MS analysis: C46H54N9ClO5S3 376 
expected 943.3, found 944.3 [M+H+].    377 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 9.00 (s, 1H), 7.47-7.41 (m, 8H), 4.29 (s, 1H), 4.68-4.65 378 
(m, 1H), 4.57 (t, J = 8.3 Hz, 1H), 4.51-4.39 (m, 3H), 3.93-3.90 (m, 1H), 3.51 (dd, J = 10.9 Hz, J = 379 
4.0 Hz, 1H), 3.44-3.39 (m, 1H), 3.28-3.16 (m, 3H), 2.73 (s, 3H), 2.62-2.59 (m, 2H), 2.48 (s, 3H), 380 
2.45 (s, 3H), 2.27-2.22 (m, 1H), 2.14-2.07 (s, 1H), 2.00 (s, 3H), 1.70 (s, 3H), 1.65-1.55 (m, 381 
4H)1.14 (s, 3H), 1.36 (s, 3H).   382 
13C-NMR (101 MHz, CD3OD, 25 °C) 174.4, 173.2, 172.6, 171.5, 166.7, 157.0, 153.5,152.6, 383 
148.4, 140.6, 138.4, 137.8, 134.0, 133.9, 133.5, 132.4, 132.2, 131.6, 131.3, 130.7, 130.6, 384 
130.0, 129.7, 129.3, 71.1, 61.2, 58.1, 57.3, 55.1, 43.7, 40.1, 39.2, 38.7, 30.0, 29.0, 28.0, 26.2, 385 
25.8, 22.5, 15.6, 14.6, 13.1.  386 
  387 
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(2S,4R)-1-((R)-2-acetamido-3-((2-(2-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-388 
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)ethyl)thio)-3-389 
methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 390 
(3) 391 
 392 
 393 
 394 
Compound 16 (9.0 mg, 0.015 mmol) was dissolved in methanol (1 ml). Catalytic amount of 395 
palladium on charcoal (10% w/w) was added and the reaction mixture stirred under an 396 
atmosphere of hydrogen for 3 h at room temperature. The reaction mixture was filtered 397 
through a syringe filter and the resulting solution evaporated to dryness to obtain the 398 
desired amine 22 which was dissolved in DMF (0.5 mL) and added to a solution of (S)-2-(4-399 
(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-400 
yl)acetic acid (+)-JQ1-COOH (6.1 mg, 0.015 mmol), HATU (6.0 mg, 0.015 mmol), HOAT (2.0 401 
mg, 0.015 mmol) and DIPEA (8.0 µl, 0.045 mmol) in DMF (0.5 mL). After stirring at room 402 
temperature for 1 h, the reaction was quenched with water (0.1 mL) and the mixture of 403 
water/DMF was removed under high vacuum at room temperature (overnight). The crude 404 
mixture was dissolved in MeOH, filtered and purified by preparative HPLC to give the title 405 
compound. Obtained 10.1 mg, 70% yield.  MS analysis: C46H54ClN9O6S3 expected 959.3, 406 
found 960.3 [M+H+].    407 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.98 (s, 1H), 8.49 (t, J = 6.0 Hz, 1H), 8.15 (d, J = 9.0 Hz, 408 
1H), 7.47-7.39 (m, 9H), 4.94-4.92 (m, 1H), 4.68-4.64 (m, 1H), 4.58 (t, J = 8.4 Hz, 1H), 4.47-409 
4.38 (m, 3H), 3.89-3.88 (m, 2H), 3.61-3.53 (m, 4H), 3.47-3.38 (m, 3H), 2.81-2.78 (m, 2H), 2.72 410 
(s, 3H), 2.47 (s, 3H), 2.45 (s, 3H), 2.27-2.22 (m, 1H), 2.14-2.07 (m, 1H), 2.00 (s, 3H), 1.70 (s, 411 
3H), 1.40 (s, 3H), 1.35 (s, 3H).   412 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.2, 172.9, 171.4, 166.6, 157.0, 153.3, 152.5, 413 
148.5, 140.5, 138.4, 137.9, 133.9, 133.8. 133.6, 132.3, 132.1, 131.6, 131.4, 130.6, 130.5, 414 
130.0, 129.6, 129.3, 71.6, 71.1, 70.5, 61.2, 58.1, 57.4, 55.1, 43.8, 40.6, 39.2, 38.6, 29.6, 26.5, 415 
26.0, 22.5, 15.7, 14.6, 13.1, 11.7. 416 
  417 
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(2S,4R)-1-((R)-2-acetamido-3-((3-(3-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-418 
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propoxy)propyl)thio)-3-419 
methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 420 
(4) 421 
 422 
 423 
 424 
Prepared as described for 1 starting from compound 24. Obtained 6.0 mg (68% yield) after 425 
preparative HPLC purification.  MS analysis: C48H58N9ClO6S3 expected 987.3, found 988.3 426 
[M+H+].    427 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.27 (s, 1H), 7.45-7.39 (m, 8H), 4.91 (s, 1H), 4.63-4.54 428 
(m, 2H), 4.52-4.38 (m, 3H), 3.93-3.91 (m, 1H), 3.86 (dd, J = 10.8 Hz, J = 3.8 Hz, 1H), 3.49-3.26 429 
(m, 10H), 2.68 (s, 3H), 2.64-3.61 (m, 2H),  2.45 (s, 3H), 2.44 (s, 3H), 2.27-2.16 (m, 1H), 2.13-430 
2.06 (m, 1H), 2.00 (s, 3H), 1.81-1.78 (m, 2H), 1.72-1.70 (m, 5H), 1.39 (s, 3H), 1.35 (s, 3H).   431 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.2, 172.8, 171.6, 166.4, 157.2, 153.0, 152.3, 432 
149.2, 140.3, 138.3, 138.1, 133.7, 133.5, 133.4, 132.2, 132.1, 131.8, 131.5, 130.6, 129.9, 433 
129.2, 71.1, 70.7, 69.5, 61.2, 58.1, 57.4, 55.4, 43.7, 39.2, 39.0, 38.0, 31.0, 30.8, 26.2, 25.8, 434 
22.5, 16.0, 14.6, 13.1, 11.8. 435 
  436 
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(2S,4R)-1-((R)-2-acetamido-3-((4-(2-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-437 
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)butyl)thio)-3-438 
methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 439 
(5) 440 
 441 
 442 
 443 
Prepared as described for 3 from azide 19. Obtained 9.2 mg (62% yield) after preparative 444 
HPLC purification. MS analysis: C48H58N9ClO6S3 expected 987.3, found 988.3 [M+H+].    445 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.87 (s, 1H), 8.43-8.37 (m, 2H exch), 8.12 (d, J = 9.4 Hz, 446 
1H exch), 7.46-7.39 (m, 8H), 4.92-4.90 (m, 1H), 4.64-4.55 (m, 2H), 4.51-4.38 (m, 3H), 3.93-447 
3.90 (m, 1H), 3.85 (dd, J = 10.8 Hz, J = 3.9 Hz, 1H), 3.53-3.41 (m, 7H), 2.69(s, 3H), 2.57 (t, J = 448 
7.1 Hz, 2H),  2.47 (s, 3H), 2.44 (s, 3H), 2.87-2.22 (m, 1H), 2.14-2.07 (m, 1H), 2.00 (s, 3H), 1.69 449 
(s, 3H),  1.62-1.52 (m, 4H), 1.38 (s, 3H), 1.35 (s, 3H).   450 
13C-NMR (101 MHz, CD3OD, 25 °C) δ: 174.4, 173.2, 173.1, 171.6, 166.3, 157.2, 153.0, 152.3, 451 
149.2, 140.3, 138.3, 138.1, 133.7, 133.5, 133.4, 132.2, 132.1, 131.8, 131.5, 130.6, 129.9, 452 
129.2, 71.7, 71.0, 70.4, 61.2, 58.1, 57.4, 55.3, 43.7, 40.7, 39.2, 38.9, 30.3, 29.2, 27.5, 26.2, 453 
25.9, 22.5, 16.0, 14.6, 13.1, 11.8. 454 
  455 
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(2S,4R)-1-((R)-14-acetamido-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-456 
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-13,13-dimethyl-2-oxo-6,9-dioxa-12-thia-3-457 
azapentadecan-15-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-458 
carboxamide (6) 459 
 460 
 461 
 462 
Prepared as described for 3 starting from azide 20. Obtained 8.4 mg (60% yield) after 463 
preparative HPLC purification. MS analysis: C48H58N9ClO7S3 expected 1,003.3, found 1,004.3 464 
[M+H+].    465 
1H-NMR (400 MHz, CD3OD, 25 °C) δ: 8.86 (s, 1H), 7.46-7.39 (m, 8H), 4.91 (s, 1H), 4.64-4.60 466 
(m, 1H), 4.57 (t, J = 8.3 Hz, 1H), 4.49-4.43 (m, 3H), 3.90-3.89 (m, 2H), 3.61-3.41 (m, 12H), 467 
3.33-3.22 (m, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.69(s, 3H), 2.46 (s, 3H), 2.44 (s, 3H), 2.28-2.22 (m, 468 
1H), 2.13-2.06 (m, 1H), 1.99 (s, 3H), 1.69 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H).   469 
13C-NMR (101 MHz, CD3OD, 25 °C) δ:174.4, 173.2, 173.0, 171.5, 166.3, 157.2, 153.0, 152.3, 470 
149.2, 140.3, 138.3, 138.1, 133.7, 133.5, 133.3, 132.2, 132.1, 131.7, 131.5, 130.5, 129.9, 471 
129.3, 71.8, 71.5, 71.1, 70.8, 61.2, 58.1, 57.4, 55.3, 43.7, 40.7, 39.2, 38.9, 29.5, 26.3, 25.9, 472 
22.5, 16.0, 14.6, 13.1, 11.8. 473 
 474 
  475 
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